[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2754
1. Hayashi S, Yamamoto M, Tachibana K, Ueno Y, Bu G, Fukushima T: Mechanism of photofrin-enhanced ultrasound-induced human glioma cell death. Anticancer Res; 2009 Mar;29(3):897-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of photofrin-enhanced ultrasound-induced human glioma cell death.
  • BACKGROUND: Low-intensity ultrasound showed tumor cell killing by a non-thermal effect in human leukemia cells.
  • The aim of our study was to investigate the efficacy of low-intensity ultrasound on malignant astrocytic tumor cells with the photosensitizer, Photofrin, which is taken up by the cell surface receptor, low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP/alpha2MR).
  • MATERIALS AND METHODS: Cells were sonicated with continuous wave ultrasound with or without the presence of Photofrin (75 mg/ml) at an intensity of 0.3 W/cm(2) for a duration of 5, 15, or 30 s.
  • RESULTS: Ultrasound alone induced instant cell killing immediately after sonication in both U251MG and U105MG malignant gliomas cells.
  • CONCLUSION: This is the first report to demonstrate the usefulness of low-intensity ultrasound for the cell killing of malignant glioma cells.
  • [MeSH-major] Brain Neoplasms / therapy. Cell Survival / drug effects. Dihematoporphyrin Ether / therapeutic use. Glioma / therapy. Photosensitizing Agents / therapeutic use. Ultrasonic Therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Low Density Lipoprotein Receptor-Related Protein-1 / genetics. Low Density Lipoprotein Receptor-Related Protein-1 / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. alpha-Macroglobulins / genetics. alpha-Macroglobulins / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414325.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Low Density Lipoprotein Receptor-Related Protein-1; 0 / Photosensitizing Agents; 0 / RNA, Messenger; 0 / alpha-Macroglobulins; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


2. Kong Q, Peterson TS, Baker O, Stanley E, Camden J, Seye CI, Erb L, Simonyi A, Wood WG, Sun GY, Weisman GA: Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor. J Neurochem; 2009 Jun;109(5):1300-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heterologous expression and activation of the human P2Y(2) nucleotide receptor (P2Y(2)R) in human 1321N1 astrocytoma cells stimulates alpha-secretase-dependent cleavage of the amyloid precursor protein (APP), causing extracellular release of the non-amyloidogenic protein secreted amyloid precursor protein (sAPPalpha).
  • These results demonstrate that elevated levels of pro-inflammatory cytokines associated with neurodegenerative diseases, such as IL-1beta, can enhance non-amyloidogenic APP processing through up-regulation of the P2Y(2)R in neurons.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Guide to Pharmacology. gene/protein/disease-specific - P2Y2 receptor - data and references .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Haemost. 2005 Apr;93(4):735-42 [15841322.001]
  • [Cites] Arch Oral Biol. 2005 Jun;50(6):533-40 [15848146.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18696-702 [15778502.001]
  • [Cites] J Neurosci Res. 2005 Jun 1;80(5):683-92 [15880353.001]
  • [Cites] Mol Neurobiol. 2005;31(1-3):169-83 [15953819.001]
  • [Cites] J Neurochem. 2005 Nov;95(3):630-40 [16135088.001]
  • [Cites] Arch Pharm Res. 2005 Nov;28(11):1275-81 [16350855.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):470S-474S [16470015.001]
  • [Cites] Nature. 1997 Feb 20;385(6618):733-6 [9034191.001]
  • [Cites] J Neurochem. 1997 Mar;68(3):1183-90 [9048765.001]
  • [Cites] J Neurosci. 1997 May 1;17(9):2939-46 [9096130.001]
  • [Cites] J Neurobiol. 1997 May;32(5):469-80 [9110259.001]
  • [Cites] Neurochem Int. 1997 Jun;30(6):557-63 [9152997.001]
  • [Cites] J Neurochem. 1997 Aug;69(2):704-12 [9231730.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21096-103 [9261113.001]
  • [Cites] Am J Physiol. 1997 Sep;273(3 Pt 1):C1100-7 [9316432.001]
  • [Cites] Physiol Rev. 1997 Oct;77(4):1081-132 [9354812.001]
  • [Cites] J Neurosci. 1997 Dec 15;17(24):9415-22 [9390997.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3602-10 [9437211.001]
  • [Cites] J Neurochem. 1998 Feb;70(2):524-30 [9453546.001]
  • [Cites] Curr Med Chem. 2006;13(3):289-312 [16475938.001]
  • [Cites] Neurosci Lett. 2006 Apr 24;397(3):214-8 [16406345.001]
  • [Cites] Curr Alzheimer Res. 2006 Apr;3(2):95-108 [16611010.001]
  • [Cites] J Neurosci. 2007 Aug 29;27(35):9301-9 [17728444.001]
  • [Cites] Ann N Y Acad Sci. 2007 Dec;1122:23-34 [18077562.001]
  • [Cites] J Neurochem. 2008 Mar;104(5):1387-93 [18021299.001]
  • [Cites] Circulation. 2002 Nov 19;106(21):2720-6 [12438299.001]
  • [Cites] J Neurosci. 2002 Dec 15;22(24):10710-9 [12486164.001]
  • [Cites] Adv Exp Med Biol. 2002;513:87-113 [12575818.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):234-40 [12652650.001]
  • [Cites] J Neurosci Res. 2003 Nov 1;74(3):342-52 [14598310.001]
  • [Cites] J Clin Neurosci. 2004 Jun;11(5):456-67 [15177383.001]
  • [Cites] Curr Drug Targets. 2004 Aug;5(6):529-34 [15270199.001]
  • [Cites] J Neurosci. 2004 Sep 1;24(35):7707-17 [15342738.001]
  • [Cites] Nature. 1988 Feb 11;331(6156):530-2 [2893291.001]
  • [Cites] Exp Neurol. 1988 Nov;102(2):264-8 [2460367.001]
  • [Cites] EMBO J. 1989 Dec 1;8(12):3627-32 [2583112.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Dec 29;165(3):1406-14 [2514687.001]
  • [Cites] FEBS Lett. 1991 Nov 4;292(1-2):171-8 [1959603.001]
  • [Cites] Mol Neurobiol. 1991;5(2-4):389-98 [1823142.001]
  • [Cites] Science. 1992 Oct 9;258(5080):304-7 [1411529.001]
  • [Cites] J Neurosci Res. 1994 Apr 15;37(6):777-87 [8046778.001]
  • [Cites] Neurosci Lett. 1994 Aug 1;176(2):133-6 [7830934.001]
  • [Cites] J Neural Transm Suppl. 1994;44:21-7 [7897393.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3032-5 [7708769.001]
  • [Cites] Arzneimittelforschung. 1995 Mar;45(3A):435-8 [7763340.001]
  • [Cites] J Neurochem. 1995 Oct;65(4):1431-44 [7561836.001]
  • [Cites] J Neurochem. 1996 Jun;66(6):2300-10 [8632152.001]
  • [Cites] J Neurochem. 1996 Nov;67(5):1882-96 [8863493.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):831-6 [9023342.001]
  • [Cites] Nature. 1997 Feb 20;385(6618):729-33 [9034190.001]
  • [Cites] Biochemistry. 1998 Feb 10;37(6):1680-5 [9484239.001]
  • [Cites] Brain Res. 1998 Jan 12;780(2):294-303 [9507169.001]
  • [Cites] J Neurosci. 1998 Apr 15;18(8):2907-13 [9526007.001]
  • [Cites] Ann N Y Acad Sci. 1998 Apr 15;842:70-5 [9599295.001]
  • [Cites] J Neurosci. 2000 Jan 1;20(1):149-55 [10627591.001]
  • [Cites] FASEB J. 2000 May;14(7):1015-22 [10783157.001]
  • [Cites] Br J Anaesth. 2000 Apr;84(4):476-88 [10823099.001]
  • [Cites] Exp Neurol. 2000 Jun;163(2):388-91 [10833312.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Aug;279(2):C286-94 [10912994.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Sep;20(9):2064-9 [10978250.001]
  • [Cites] Trends Neurosci. 2000 Dec;23(12):618-25 [11137152.001]
  • [Cites] J Neurosci Res. 2001 Mar 1;63(5):410-20 [11223916.001]
  • [Cites] Nat Med. 2001 May;7(5):612-8 [11329064.001]
  • [Cites] Int J Dev Neurosci. 2001 Jul;19(4):395-414 [11378300.001]
  • [Cites] Science. 2001 Aug 24;293(5534):1449-54 [11520976.001]
  • [Cites] Nat Rev Neurosci. 2001 Oct;2(10):734-44 [11584311.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):44881-8 [11584021.001]
  • [Cites] Biochemistry. 2002 Apr 16;41(15):4972-81 [11939793.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Jun 15;102(1-2):62-72 [12191495.001]
  • [Cites] J Neurosci Res. 2002 Nov 1;70(3):462-73 [12391607.001]
  • [Cites] Br J Pharmacol. 1998 Jun;124(3):428-30 [9647463.001]
  • [Cites] J Neurochem. 1999 Feb;72(2):443-60 [9930716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3922-7 [10097139.001]
  • [Cites] Biochem J. 1999 Oct 15;343 Pt 2:371-5 [10510302.001]
  • [Cites] Subcell Biochem. 2005;38:105-27 [15709475.001]
  • (PMID = 19317852.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG018357-079002; United States / NIA NIH HHS / AG / P01 AG018357; United States / NIA NIH HHS / AG / P01 AG018357-079002; United States / NIA NIH HHS / AG / P01 AG18357
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Enzyme Inhibitors; 0 / Interleukin-1beta; 0 / Nucleotides; 0 / P2RY2 protein, human; 0 / P2ry2 protein, rat; 0 / RNA, Messenger; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2Y2; 57716-89-9 / 4-O-methyl-12-O-tetradecanoylphorbol 13-acetate; EC 3.4.- / Amyloid Precursor Protein Secretases; NI40JAQ945 / Tetradecanoylphorbol Acetate; UT0S826Z60 / Uridine Triphosphate
  • [Other-IDs] NLM/ NIHMS104072; NLM/ PMC2710802
  •  go-up   go-down


3. Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA: Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys; 2006 Mar 1;64(3):892-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results.
  • PURPOSE: To report preliminary clinical and dosimetric data from intensity-modulated radiotherapy (IMRT) for malignant gliomas.
  • METHODS AND MATERIALS: Fifty-eight consecutive high-grade gliomas were treated between January 2001 and December 2003 with dynamic multileaf collimator IMRT, planned with the inverse approach.
  • The median progression-free survival time for anaplastic astrocytoma and glioblastoma histology was 5.6 and 2.5 months, respectively.
  • The overall survival time for anaplastic glioma and glioblastoma was 36 and 9 months, respectively.
  • A comparative dosimetric analysis revealed that regardless of tumor location, IMRT did not significantly improve target coverage compared with three-dimensional planning.
  • CONCLUSIONS: It is unlikely that IMRT will improve local control in high-grade gliomas without further dose escalation compared with conventional radiotherapy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / radiation effects. Disease Progression. Female. Glioblastoma / radiotherapy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Oligodendroglioma / radiotherapy. Radiotherapy Dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458777.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Beckner ME, Chen X, An J, Day BW, Pollack IF: Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest; 2005 Mar;85(3):316-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas (astrocytomas) are lethal tumors that invade the brain.
  • In this study, U87 glioma cells formed pseudopodia in vitro as cells pushed through 3 microm pores of polycarbonate membranes.
  • Increased constituents of the pseudopodial proteome in glioma cells, identified in this study as actin, HGF, Met, and isoforms of AnxI, AnxII, and several glycolytic enzymes, represent therapeutic targets to consider for suppression of tumor invasion.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor. Brain Neoplasms / pathology. Proteome. Pseudopodia / metabolism
  • [MeSH-minor] Annexin A1 / metabolism. Annexin A2 / metabolism. Antibodies, Neoplasm / immunology. Electrophoresis, Gel, Two-Dimensional. Fructose-Bisphosphate Aldolase / metabolism. Hepatocyte Growth Factor / metabolism. Humans. Mitogens / metabolism. Neoplasm Invasiveness. Phosphopyruvate Hydratase / metabolism. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654357.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Annexin A2; 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / HGF protein, human; 0 / Mitogens; 0 / Proteome; 67256-21-7 / Hepatocyte Growth Factor; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


5. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, McKnight TR, Goldman SA, Weiss WA: Non-stem cell origin for oligodendroglioma. Cancer Cell; 2010 Dec 14;18(6):669-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant astrocytic brain tumors are among the most lethal cancers.
  • Quiescent and therapy-resistant neural stem cell (NSC)-like cells in astrocytomas are likely to contribute to poor outcome.
  • Using magnetic resonance imaging (MRI) and detailed developmental analyses, we demonstrated that murine oligodendroglioma cells show characteristics of oligodendrocyte progenitor cells (OPCs) and are therapy sensitive, and that OPC rather than NSC markers enriched for tumor formation.
  • MRI of human oligodendroglioma also suggested a white matter (WM) origin, with markers for OPCs rather than NSCs similarly enriching for tumor formation.
  • Our results suggest that oligodendroglioma cells show hallmarks of OPCs, and that a progenitor rather than a NSC origin underlies improved prognosis in patients with this tumor.
  • [MeSH-minor] Animals. Antigens / analysis. Benzamides / pharmacology. Cell Differentiation. Cell Line, Tumor. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Diphenylamine / analogs & derivatives. Diphenylamine / pharmacology. Humans. Mice. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Oncogene Proteins v-erbB / analysis. Proteoglycans / analysis. Tumor Suppressor Protein p53 / physiology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N,N-DIPHENYLAMINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Nature. 2008 May 8;453(7192):228-32 [18418377.001]
  • [Cites] Mol Cancer. 2008;7:41 [18492260.001]
  • [Cites] Neuron. 2008 Jun 26;58(6):832-46 [18579075.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10051-9 [19074870.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Nat Med. 2009 Jan;15(1):110-6 [19122659.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):135-47 [19185848.001]
  • [Cites] Mol Cell Biol. 2009 Mar;29(6):1538-53 [19139271.001]
  • [Cites] Cell Stem Cell. 2009 Mar 6;4(3):226-35 [19265662.001]
  • [Cites] NMR Biomed. 2009 May;22(4):449-55 [19125391.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):440-52 [19427293.001]
  • [Cites] Stem Cells. 2009 Aug;27(8):2032-43 [19544429.001]
  • [Cites] PLoS One. 2009;4(11):e7752 [19915670.001]
  • [Cites] Nature. 2010 Jan 21;463(7279):318-25 [20032975.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):98-110 [20129251.001]
  • [Cites] J Neurosci. 2000 Sep 1;20(17):6404-12 [10964946.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3826-36 [11325859.001]
  • [Cites] J Neurosci Res. 2002 Sep 15;69(6):837-47 [12205677.001]
  • [Cites] J Comp Neurol. 2003 Mar 17;457(4):404-19 [12561079.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] Neurosci Lett. 2003 Aug 21;347(2):111-5 [12873740.001]
  • [Cites] Mol Cell Neurosci. 2003 Oct;24(2):476-88 [14572468.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8930-8 [14695210.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11334-7 [15273287.001]
  • [Cites] J Cell Biol. 2004 Sep 27;166(7):963-8 [15452140.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Neuron. 1993 Feb;10(2):201-12 [8439409.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5649-51 [7923211.001]
  • [Cites] EMBO J. 1997 Jan 15;16(2):306-17 [9029151.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6 [10468613.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] Glia. 2005 Aug 1;51(2):81-97 [15782413.001]
  • [Cites] Ann Neurol. 2006 May;59(5):763-79 [16634042.001]
  • [Cites] J Neurosci. 2006 Jul 26;26(30):7907-18 [16870736.001]
  • [Cites] Glia. 2007 Jan 15;55(2):165-77 [17078026.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] BMC Dev Biol. 2007;7:17 [17362503.001]
  • [Cites] Development. 2008 Jan;135(1):145-57 [18045844.001]
  • [Cites] J Neurosci. 2008 Jan 23;28(4):914-22 [18216199.001]
  • [Cites] Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5 [18382330.001]
  • [Cites] Brain Pathol. 2010 Mar;20(2):399-411 [19486010.001]
  • [CommentIn] Cancer Cell. 2010 Dec 14;18(6):546-7 [21156279.001]
  • (PMID = 21156288.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NIGMS NIH HHS / GM / R01 GM081635; United States / NCI NIH HHS / CA / R01 CA095287; United States / NCI NIH HHS / CA / P50 CA097257-09; United States / NCI NIH HHS / CA / P50 CA097257-08; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / P50 CA097257-07; United States / NCI NIH HHS / CA / P50 CA097257-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Benzamides; 0 / Oncogene Proteins v-erbB; 0 / PD 0325901; 0 / Proteoglycans; 0 / Tumor Suppressor Protein p53; 0 / chondroitin sulfate proteoglycan 4; 7GR28W0FJI / Dacarbazine; 9N3CBB0BIQ / Diphenylamine; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ NIHMS250124; NLM/ PMC3031116
  •  go-up   go-down


6. Ramos Martínez A, Sánchez Romero I, Saura Lorente PA, Parajón Díaz A: [Suppurative thrombophlebitis central venous catheterization]. An Med Interna; 2008 Jun;25(6):284-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 22-year-old colombian-woman, student, without toxic habits was admitted because of temporary left astrocytoma (grade II).

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. CLOXACILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295976.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticoagulants; 0 / Gentamicins; 0 / Heparin, Low-Molecular-Weight; O6X5QGC2VB / Cloxacillin
  •  go-up   go-down


7. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol; 2008 Jan 10;26(2):271-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
  • PURPOSE: The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas.
  • The aim of these retrospective studies was to evaluate tumor vascularity and expression of components of the VEGF pathway and hypoxic responses as predictive markers for radiographic response and survival benefit from the bevacizumab and irinotecan therapy.
  • PATIENTS AND METHODS: In a phase II trial, 60 patients with recurrent malignant astrocytomas were treated with bevacizumab and irinotecan.
  • Tumor specimens collected at the time of diagnosis were available for further pathologic studies in 45 patients (75%).
  • RESULTS: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma.
  • CONCLUSION: In this patient cohort, tumor expression levels of VEGF, the molecular target of bevacizumab, were associated with radiographic response, and the upstream promoter of angiogenesis, hypoxia, determined survival outcome, as measured from treatment initiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Hypoxia. Male. Middle Aged. Neovascularization, Pathologic. Proportional Hazards Models. Radiography. Retrospective Studies. Survival Analysis. Treatment Outcome. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Nat Clin Pract Neurol. 2006 May;2(5):232-3 [16932555.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5260-4 [17000656.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6130-4 [14559790.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 18182667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS054276; United States / NCI NIH HHS / CA / R01 CA116659; United States / NCI NIH HHS / CA / CA116659; United States / NINDS NIH HHS / NS / K02 NS047409; United States / NINDS NIH HHS / NS / NS047409; United States / NINDS NIH HHS / NS / R01 NS054276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS508913; NLM/ PMC3930173
  •  go-up   go-down


8. Temel SG, Minbay FZ, Kahveci Z, Jennes L: Microwave-assisted antigen retrieval and incubation with cox-2 antibody of archival paraffin-embedded human oligodendroglioma and astrocytomas. J Neurosci Methods; 2006 Sep 30;156(1-2):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microwave-assisted antigen retrieval and incubation with cox-2 antibody of archival paraffin-embedded human oligodendroglioma and astrocytomas.
  • Here we assess the effect of microwave irradiation on the incubation time required to obtain high quality immunohistochemical staining for cox-2 using archival formalin-fixed, paraffin-embedded human oligodendrogliomas and astrocytomas.
  • Thus, the use of this procedure results in a significant saving of time which is important for a timely diagnosis of pathological conditions that await treatment.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Astrocytoma / immunology. Brain Neoplasms / immunology. Cyclooxygenase 2 / immunology. Oligodendroglioma / immunology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621014.001).
  • [ISSN] 0165-0270
  • [Journal-full-title] Journal of neuroscience methods
  • [ISO-abbreviation] J. Neurosci. Methods
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Fixatives; 1HG84L3525 / Formaldehyde; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


9. López-Aguilar E, Sepúlveda Vildósola AC, Rioscovián-Soto AP, Gascón-Lastiri G, Rojas-Puentes F, Siordia-Reyes G, Diegopérez-Ramírez J, De la Cruz-Yáñez H, Barrientos-Salcedo C: [Survival of patients with malignant astrocytomas according to the expression of Ki67 antigen in a pediatric hospital]. Gac Med Mex; 2010 Mar-Apr;146(2):118-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival of patients with malignant astrocytomas according to the expression of Ki67 antigen in a pediatric hospital].
  • [Transliterated title] Sobrevida de los pacientes con astrocitoma de alto grado que expresan el antígeno Ki67, atendidos en un hospital de pediatría.
  • BACKGROUND: Pediatric patients with malignant gliomas and same histological diagnosis respond distinctly to treatment.
  • The aim of this study was to determine if the expression of this antigen influences survival of patients treated for malignant gliomas in the CMN SXXI Pediatrics Hospital.
  • METHODS: We included patients with anaplasic astrocitoma or glioblastoma multiforme seen at our hospital between 1995 and 2005.
  • We determined the expression of Ki67 by immunohistochemistry and correlated the findings with tumor histology and patient survival.
  • CONCLUSIONS: Being young (under 11 years) is a marker of poor prognosis among pediatric patients with anaplasic astrocytoma or glioblastoma multiforme.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / mortality. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Ki-67 Antigen / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626127.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


10. Sawamura Y, Kamoshima Y, Kato T, Tajima T, Tsubaki J: Chemotherapy with cisplatin and vincristine for optic pathway/hypothalamic astrocytoma in young children. Jpn J Clin Oncol; 2009 May;39(5):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with cisplatin and vincristine for optic pathway/hypothalamic astrocytoma in young children.
  • OBJECTIVE: Optic pathway/hypothalamic astrocytomas (OPHA) in young children often show accelerated growth and require rather intensive induction chemotherapy.
  • All of them presented with progressive disease, and the tumor size was larger than 34 mm.
  • Pilocytic astrocytoma was confirmed histologically in 10 patients.
  • Although the remaining four cases were evaluated as stable disease, all tumors decreased in volume.
  • CONCLUSION: Although the present series was small, this chemotherapy is a useful regimen for induction therapy in children with an aggressive deep-seated pilocytic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Hypothalamic Neoplasms / drug therapy. Visual Pathways

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224939.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Nowak-Sadzikowska J, Gliński B, Szpytma T, Pluta E: Postoperative irradiation of incompletely excised gemistocytic astrocytomas. Clinical outcome and prognostic factors. Strahlenther Onkol; 2005 Apr;181(4):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative irradiation of incompletely excised gemistocytic astrocytomas. Clinical outcome and prognostic factors.
  • BACKGROUND AND PURPOSE: Although gemistocytic astrocytomas are considered slow-growing tumors, they often behave aggressively and carry the least favorable prognosis among low-grade astrocytomas.
  • The aim of this study is to evaluate the outcomes and prognostic factors of patients with incompletely excised gemistocytic astrocytomas irradiated postoperatively.
  • PATIENTS AND METHODS: Records of 48 patients with incompletely excised gemistocytic astrocytoma, irradiated between 1976 and 1998 at the Department of Radiation Oncology, Maria Skłodowska-Curie Memorial Cancer Center, Cracow, Poland, were reviewed.
  • The treatment volume covered the residual tumor with a margin of 1-2 cm.
  • CONCLUSION: In most patients with gemistocytic astrocytoma, combined surgery and postoperative radiotherapy result in only short-term survival.
  • Older age is the most important unfavorable prognostic factor in patients with gemistocytic astrocytoma.
  • [MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827694.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Gandhari MK, Frazier CR, Hartenstein JS, Cloix JF, Bernier M, Wainer IW: Identification and characterization of estrogen receptor-related receptor alpha and gamma in human glioma and astrocytoma cells. Mol Cell Endocrinol; 2010 Feb 5;315(1-2):314-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of estrogen receptor-related receptor alpha and gamma in human glioma and astrocytoma cells.
  • The purpose of this study was to examine expression and function of estrogen receptor-related receptors (ERRs) in human glioma and astrocytoma cell lines.
  • These estrogen receptor-negative cell lines expressed ERRalpha and ERRgamma proteins to varying degree in a cell context dependent manner, with U87MG glioma cells expressing both orphan nuclear receptors.
  • These results indicate that ERRalpha and ERRgamma are differentially expressed in these tumor cell lines and likely contribute to agonist-dependent ERR transcriptional activity.
  • [MeSH-major] Astrocytoma / metabolism. Glioma / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Humans. Promoter Regions, Genetic. Transcriptional Activation

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Mol Endocrinol. 2000 Mar;14(3):382-92 [10707956.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):886-91 [1991261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8880-4 [11447273.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):303-13 [11864604.001]
  • [Cites] Trends Endocrinol Metab. 2002 Jul;13(5):220-5 [12185669.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Dec 20;299(5):872-9 [12470660.001]
  • [Cites] Cancer J. 2003 May-Jun;9(3):149-56 [12952300.001]
  • [Cites] Arch Pharm Res. 2003 Sep;26(9):756-62 [14560926.001]
  • [Cites] Mol Cancer Res. 2003 Nov;1(13):981-91 [14638870.001]
  • [Cites] J Mol Endocrinol. 2003 Dec;31(3):349-57 [14664699.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 20;314(4):964-70 [14751226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7 [15184675.001]
  • [Cites] Gene. 2004 Oct 13;340(2):275-82 [15475169.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5147-51 [7139616.001]
  • [Cites] Nature. 1988 Jan 7;331(6151):91-4 [3267207.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):833-8 [11297507.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):513-29 [7844613.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8908-17 [18974135.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):224-6 [8613997.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Jun;100(2):89-93 [9746294.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22618-26 [10428842.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49330-7 [15337744.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9115-23 [15604281.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Mar 1;15(5):1311-3 [15713377.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1830-44 [15598686.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):12-26 [16443944.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):47-52 [16443947.001]
  • [Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]
  • [Cites] Curr Top Med Chem. 2006;6(3):203-15 [16515477.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Cell. 2006 Aug 25;126(4):789-99 [16923397.001]
  • [Cites] Mol Cell Endocrinol. 2007 Jan 29;264(1-2):128-41 [17157980.001]
  • [Cites] Neuroscience. 2007 Mar 30;145(3):795-811 [17320297.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28328-34 [17631492.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):23-31 [17962013.001]
  • [Cites] Endocr Rev. 2008 Oct;29(6):677-96 [18664618.001]
  • [Cites] Can J Neurol Sci. 1995 Nov;22(4):264-71 [8599768.001]
  • (PMID = 19822186.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 AG999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / ERRalpha estrogen-related receptor; 0 / ESRRG protein, human; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ NIHMS151930; NLM/ PMC2815036
  •  go-up   go-down


13. Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Umetsu A, Sato A, Yamada T, Takahashi S: Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology; 2006 Dec;241(3):839-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis.
  • PURPOSE: To retrospectively assess the apparent diffusion coefficient (ADC) for prediction of malignancy and prognosis of malignant astrocytic tumors.
  • Findings from 37 consecutive patients (21 men, 16 women; mean age, 43 years) with pathologically proved malignant astrocytic tumors that included 22 glioblastomas (GBMs) and 15 anaplastic astrocytomas (AAs) were retrospectively evaluated.
  • The minimum ADC value of each tumor was preoperatively determined from several regions of interest defined in the tumor, preferably with avoidance of cystic or necrotic components, on ADC maps derived from isotropic diffusion-weighted images.
  • CONCLUSION: The minimum ADC of malignant astrocytomas can provide additional information about their clinical malignancy related to posttreatment prognosis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans. Image Processing, Computer-Assisted. Ki-67 Antigen / analysis. Male. Predictive Value of Tests. Prognosis. ROC Curve. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 17032910.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


14. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A, Parada LF: Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell; 2009 Jan 6;15(1):45-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.
  • Malignant astrocytomas are infiltrative and incurable brain tumors.
  • We previously reported mouse models based on conditional inactivation of the human astrocytoma-relevant tumor suppressors p53, Nf1, and Pten, wherein through somatic loss of heterozygosity, mutant mice develop tumors with 100% penetrance.
  • In the present study, we show that tumor suppressor inactivation in neural stem/progenitor cells is both necessary and sufficient to induce astrocytoma formation.
  • Tumor suppressor heterozygous neural stem/progenitor cultures from presymptomatic mice show aberrant growth advantage and altered differentiation, thus identifying a pretumorigenic cell population.


15. Cui XL, Zhao ZG, Ren XH, Sui DL, Chu JS, Tang K, Zeng C, Lin S: [Characteristics of combining loss of heterozygosity of 1p/19q in glioma]. Zhonghua Wai Ke Za Zhi; 2010 Jun 1;48(11):852-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of combining loss of heterozygosity of 1p/19q in glioma].
  • METHODS: The status of 1p and 19q of 138 glioma specimen from January 2009 to December 2009 was evaluated by Fluorescence in situ hybridization (FISH) method, and the frequencies of combining LOH of 1p/19q were compared between different pathologies, brain sub-regions, genders and ages.
  • RESULTS: The frequencies of combined LOH of 1p and 19q of oligodendroglial (81.3%) and oligo astrocytic tumors (55.8%) were significantly higher than that of astrocytic tumor (22.2%) (P < 0.01), and the frequency of oligodendroglial tumor was significantly higher than that of oligo astrocytic tumor (P < 0.05).
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Loss of Heterozygosity

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21163056.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Massimi L, Battaglia D, Paternoster G, Martinelli D, Sturiale C, Di Rocco C: Segmental spinal myoclonus and metastatic cervical ganglioglioma: an unusual association. J Child Neurol; 2009 Mar;24(3):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Segmental spinal myoclonus rarely occurs in association with spinal cord tumor.
  • Only 3 cases have been reported in children so far, mainly concerning astrocytomas of the thoracic spinal cord.
  • We report on a 2-year-old boy suffering from segmental spinal myoclonus involving the upper limbs and harboring a cervical tumor.
  • Neuroimaging and histological examinations showed the exceptional presence of a ganglioglioma as the cause of the segmental spinal myoclonus.

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Myoclonus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258299.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Santhanam R, Balasubramaniam A, Chandramouli BA: Fatal intratumoral hemorrhage in posterior fossa tumors following ventriculoperitoneal shunt. J Clin Neurosci; 2009 Jan;16(1):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An eight-year-old girl presented with raised intracranial pressure and ataxia caused by vermian astrocytoma with obstructive hydrocephalus.
  • She also developed a massive tumor bleed following a ventriculoperitoneal shunt and was subjected to emergency decompression of the tumor with the bleeding.
  • [MeSH-major] Astrocytoma / surgery. Infratentorial Neoplasms / surgery. Intracranial Hemorrhages / etiology. Ventriculoperitoneal Shunt / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013806.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


18. Jacques TS, Eldridge C, Patel A, Saleem NM, Powell M, Kitchen ND, Thom M, Revesz T: Mixed glioneuronal tumour of the fourth ventricle with prominent rosette formation. Neuropathol Appl Neurobiol; 2006 Apr;32(2):217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our cases demonstrate the morphological features of the 'rosette-forming glioneuronal tumour of the fourth ventricle', a recently identified tumour characterised by its unique location, neurocytic pseudo-rosette formation and the presence of a low grade astrocytoma component.
  • [MeSH-minor] Adult. Astrocytoma / metabolism. Astrocytoma / pathology. Astrocytoma / physiopathology. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neurocytoma / metabolism. Neurocytoma / pathology. Neurocytoma / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599951.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Crabtree KL, Arnold PM: Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously. Pediatr Neurosurg; 2010;46(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously.
  • Pilocytic astrocytoma (PA) is a slow-growing, well-circumscribed grade I glioma generally considered benign, with a low recurrence rate and an excellent prognosis following complete surgical resection.
  • PA is the most common central nervous system glioma in the pediatric population and is rare in adults.
  • To our knowledge, this is the longest time reported from initial tumor resection of leptomeningeal dissemination to the distal spinal cord.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasm Seeding. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516744.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Pisarev VB, Golub BV, Smirnov AV, Gurov DIu: [Prevalence of different histological types of brain tumors in the volgograd region according to the data of intraoperative biopsies over the period of 2001 to 2006]. Arkh Patol; 2008 Jul-Aug;70(4):17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas were a dominant group (51.9%) at all study time intervals.
  • Among them, there was a preponderance of glioblastomas (24.7%), anaplastic astrocytomas (21.1%), protoplasmatic astrocytomas (15.4%).
  • The fact that heterogenic tumor tissue in a great deal of the study cases of malignant gliomas makes pathohistologists' opinion differ and suggests that there is a need for an in-depth study of intraoperative biopsy specimens, by using the existing antibody panels and developing new ones for immunohistochemical studies.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807520.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


21. Kim SH, Kang SS, Jung TY, Jung S: Juvenile pilomyxoid astrocytoma in the opticohypothalamus. J Korean Neurosurg Soc; 2010 Nov;48(5):445-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile pilomyxoid astrocytoma in the opticohypothalamus.
  • Pilomyxoid astrocytoma (PMA) is a newly recognized variant of a pilocytic astrocytoma.
  • This report describes a case of a pilomyxoid astrocytoma that occurred in the opticohypothalamus.
  • Magnetic resonance imaging (MRI) showed an irregular lobulated tumor with heterogeneous enhancement at the suprasellar region involving the hypothalamus.
  • Adjuvant chemotherapy with cisplatin and vincristine was started following tumor resection.
  • Although long-term outcome is yet to be determined, the administration of combined cisplatin and vincristine treatment seems to be an effective regimen for a pilomyxoid astrocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2009 Mar;29(3):919-26 [19414328.001]
  • [Cites] J Neurooncol. 1998 May;37(3):263-70 [9524084.001]
  • [Cites] Clin Neuropathol. 2001 Nov-Dec;20(6):256-62 [11758781.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):416-20 [12924720.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):72-9; discussion 79-80 [14683543.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Nov;29(10):1861-6 [18701580.001]
  • [Cites] Cancer. 1993 May 15;71(10):3165-72 [8490847.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53 [10068313.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):214-9 [10940774.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):89-93 [16521485.001]
  • [Cites] J Neurosurg. 1978 Aug;49(2):179-84 [671072.001]
  • (PMID = 21286484.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3030087
  • [Keywords] NOTNLM ; Adjuvant chemotherapy / Opticohypothalamus / Pilomyxoid astrocytoma
  •  go-up   go-down


22. Distelmaier F, Janssen G, Mayatepek E, Schaper J, Göbel U, Rosenbaum T: Disseminated pilocytic astrocytoma involving brain stem and diencephalon: a history of atypical eating disorder and diagnostic delay. J Neurooncol; 2006 Sep;79(2):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated pilocytic astrocytoma involving brain stem and diencephalon: a history of atypical eating disorder and diagnostic delay.
  • In this report we present an unusual case of severe emaciation in a 4(9)/(12)-year-old girl with a juvenile pilocytic astrocytoma of the hypothalamic region and brain stem with neuroaxis dissemination.
  • This case illustrates the importance of considering intracranial mass-lesions in the differential diagnosis of weight loss, psychological disturbance and atypical eating disorder.
  • We discuss the importance of tumor multifocality and the role of patient age in the clinical presentation with reference to the literature.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Emaciation / etiology. Feeding and Eating Disorders / etiology


23. Koos B, Peetz-Dienhart S, Riesmeier B, Frühwald MC, Hasselblatt M: O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas. Neuropathol Appl Neurobiol; 2010 Jun;36(4):356-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas.
  • [MeSH-major] Astrocytoma / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Ependymoma / genetics. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202118.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


24. Marković M, Knezević N, Momcilović M, Grgurić-Sipka S, Harhaji L, Trajković V, Mostarica Stojković M, Sabo T, Miljković D: [Pt(HPxSC)Cl(3)], a novel platinum(IV) compound with anticancer properties. Eur J Pharmacol; 2005 Jul 4;517(1-2):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present work, the anticancer action of recently synthesized Pt(IV)-based complex [Pt(HPxSC)Cl(3)] was investigated using rat and human astrocytoma cell lines C6 and U251.
  • [Pt(HPxSC)Cl(3)] markedly reduced the number of cultured astrocytoma cells (IC(50), 80 microM), as determined by crystal violet assay.
  • The Pt(IV) complex induced apoptotic death of tumor cells, as flow cytometry analysis of the propidium iodide-stained cellular DNA revealed approx.
  • 30% of hypodiploid cells in [Pt(HPxSC)Cl(3)]-treated astrocytoma cell cultures.
  • On the other hand, [Pt(HPxSC)Cl(3)] at 200 microM did not affect the viability of rat primary astrocytes, unlike the established anticancer drug cisplatin, which displayed high toxicity toward both astrocytoma cells (IC(50), 15 microM) and primary astrocytes (IC(50), 20 microM).
  • Moreover, [Pt(HPxSC)Cl(3)] at 100 microM did not interfere with the ability of rat peritoneal macrophages to produce important antitumor molecules nitric oxide and tumor necrosis factor-alpha.
  • [MeSH-minor] Animals. Astrocytoma / drug therapy. Astrocytoma / metabolism. Astrocytoma / pathology. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Coculture Techniques. DNA, Neoplasm / metabolism. Dose-Response Relationship, Drug. Humans. Interferon-gamma / pharmacology. Macrophages, Peritoneal / cytology. Macrophages, Peritoneal / drug effects. Microbial Sensitivity Tests. Nitric Oxide / metabolism. Rats. Tumor Necrosis Factor-alpha / metabolism

  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970285.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Organoplatinum Compounds; 0 / Platinum Compounds; 0 / Tumor Necrosis Factor-alpha; 31C4KY9ESH / Nitric Oxide; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


25. de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, Delalande O: Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery; 2007 Jan;60(1):83-89; discussion 89-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?
  • OBJECTIVE: A small percentage of tuberous sclerosis patients will develop a subependymal giant-cell astrocytoma.
  • METHODS: We retrospectively reviewed 19 patients treated surgically for intraventricular tumors in Foch Hospital and at the Fondation Adolphe de Rothschild in Paris, France, and we analyzed published pediatric reports from 1980 to 2006.
  • RESULTS: The results from our own population, as well as from other published pediatric series (15 series), indicate that subependymal giant-cell astrocytomas have a good prognosis when a macroscopically total resection has been performed.
  • CONCLUSION: We think that any lesion fulfilling the criteria for a subependymal giant-cell astrocytoma as previously described in the literature (lesion around the foramen of Monro, greater than 5 mm, with incomplete calcifications) should be removed as soon as clear evidence of growth has been confirmed.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Tuberous Sclerosis / surgery


26. Ech-Cherif El Kettani N, Salaheddine T, El Quessar A, El Kharras A, El Hassani MR, Chakir N, Boukhrissi N, Benameur M, Jiddane M: [Neuro-imaging of tuberous sclerosis]. J Radiol; 2006 Feb;87(2 Pt 1):109-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neuro-imagerie de la sclérose tubéreuse de Bourneville.
  • Tuberous sclerosis is a phakomatosis with central nervous system manifestations characterized by 4 lesions detectable on neuro-imaging: tubers, white matter abnormalities, subependymal nodules and subependymal astrocytomas.
  • At CT, enhancement of subependymal nodules is usually considered as evidence of transformation to subependymal giant cell astrocytoma.

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484932.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Ng WH, Wan GQ, Peng ZN, Too HP: Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas. J Clin Neurosci; 2009 Mar;16(3):427-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas.
  • Its ubiquitous presence in the central nervous system suggests a role in the mitogenesis of high-grade astrocytoma.
  • GDNF is overexpressed in glioblastoma cell lines and human gliomas.
  • GFRalpha1b is the predominant spliced receptor isoform in human gliomas and RET9 is the predominant co-receptor.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / physiology. Glial Cell Line-Derived Neurotrophic Factor / classification. Glial Cell Line-Derived Neurotrophic Factor / metabolism. Glioma / metabolism
  • [MeSH-minor] Antineoplastic Agents, Alkylating / pharmacology. Carmustine / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Ligands. Neural Cell Adhesion Molecules / genetics. Neural Cell Adhesion Molecules / metabolism. Oncogene Protein v-akt / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • Hazardous Substances Data Bank. Carmustine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138852.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glial Cell Line-Derived Neurotrophic Factor; 0 / Ligands; 0 / Neural Cell Adhesion Molecules; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; U68WG3173Y / Carmustine
  •  go-up   go-down


28. Kikuchi H: [Novel biologically active compounds isolated from unexploited organisms, cellular sime molds]. Yakugaku Zasshi; 2007 Sep;127(9):1431-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, brefelamide inhibited the cellular proliferation of 1321N1 human astrocytoma cells.
  • [MeSH-minor] Amides / isolation & purification. Amides / pharmacology. Amino Sugars / isolation & purification. Amino Sugars / pharmacology. Animals. Astrocytoma / pathology. Cell Differentiation / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Dictyostelium / chemistry. Hexanones / isolation & purification. Hexanones / pharmacology. Humans. Neurons / cytology. Phenols / isolation & purification. Phenols / pharmacology. Pyrones / isolation & purification. Pyrones / pharmacology. Rats

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827923.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amides; 0 / Amino Sugars; 0 / Biological Products; 0 / Hexanones; 0 / Phenols; 0 / Pyrones; 0 / brefelamide; 111050-72-7 / 1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone
  • [Number-of-references] 34
  •  go-up   go-down


29. Moskowitz SI, Jin T, Prayson RA: Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol; 2006 Jan;76(2):193-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Histologic immunomarkers of cell cycle proteins have been utilized for prognosis in high-grade astrocytic tumors.
  • One such marker, MIB1, an antibody immunoreactive throughout the cell cycle, is predictive of more aggressive disease and poorer prognosis in astrocytomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Ki-67 Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):997-1004 [10584846.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] J Neurosurg Sci. 2000 Dec;44(4):203-9; discussion 209-10 [11327289.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):803-8 [8598356.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer J. 2003 May-Jun;9(3):222-9 [12952307.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):179-86 [12084348.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8 [11939587.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):219-26 [15309911.001]
  • [Cites] Breast. 2003 Dec;12(6):538-42 [14659132.001]
  • [Cites] Histopathology. 2002 Jan;40(1):2-11 [11903593.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1343-7 [12091064.001]
  • [Cites] Clin Neuropathol. 2002 Nov-Dec;21(6):252-7 [12489673.001]
  • [Cites] Surg Neurol. 1999 Oct;52(4):371-9 [10555843.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):139-46 [15015779.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):124-37 [11550308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] J Neurooncol. 2000;46(1):11-6 [10896201.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Neurosurgery. 1993 May;32(5):716-20; discussion 720 [8388081.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):981-7 [9869219.001]
  • [Cites] J Neurooncol. 2002 Apr;57(2):115-21 [12125971.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):45-60; discussion 60-1 [8121569.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):319-31 [10931365.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):127-32 [11995813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14453-8 [9826721.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):795-8 [3772478.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):886-92 [14609169.001]
  • [Cites] Neurochirurgie. 1998 Mar;44(1):25-30 [9757314.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):217-36 [12187957.001]
  • [Cites] J Neurooncol. 2000;46(1):71-80 [10896207.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):674-8; discussion 678-9 [8008166.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):121-30 [8988090.001]
  • [Cites] Int J Oncol. 2003 Sep;23 (3):641-8 [12888899.001]
  • [Cites] J Neurooncol. 2003 May;63(1):9-13 [12814249.001]
  • [Cites] Surg Neurol. 1998 Dec;50(6):579-85 [9870820.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):373-80 [8625247.001]
  • [Cites] J Neurosurg Sci. 1999 Dec;43(4):263-70 [10864388.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 16234986.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


30. Mineo JF, Bordron A, Quintin-Roué I, Maurage CA, Buhé V, Loisel S, Dubois F, Blond S, Berthou C: Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model. J Neurooncol; 2006 Feb;76(3):249-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiform (GBM) remains the most devastating primary tumour in neuro-oncology.
  • HER2 is not expressed in adult glial cells, but its expression increases with the degree of astrocytomas anaplasia.
  • [MeSH-major] Brain Neoplasms / metabolism. Disease Models, Animal. Glioblastoma / metabolism. Receptor, ErbB-3 / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Membrane / metabolism. Cell Transplantation. Flow Cytometry. Humans. Immunohistochemistry. Mice. Mice, Nude. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2007 Sep;84(3):331. Isabelle, Quintin-Roué [corrected to Quintin-Roué, Isabelle]; Virginie, Buhé [corrected to Buhé, Virginie]; Séverine, Loisel [corrected to Loisel, Séverine]
  • [Cites] Neurochirurgie. 2002 Dec;48(6):500-9 [12595806.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1182-91 [7532277.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1485-95 [15196531.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1599-602 [12168843.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1457-65 [8640840.001]
  • [Cites] Med Biol. 1978 Aug;56(4):184-93 [359950.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):335-46 [9440030.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1152-60 [15718311.001]
  • [Cites] Oncogene. 1990 Jul;5(7):953-62 [1973830.001]
  • [Cites] J Neuroimmunol. 1990 Nov;30(1):81-93 [1977769.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):737-44 [8622019.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70 [10482195.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 May;18(5):510-20 [9591843.001]
  • [Cites] Eur J Cancer. 1991;27(11):1372-5 [1683776.001]
  • [Cites] J Gastrointest Surg. 2001 Mar-Apr;5(2):139-46 [11331475.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1195-9 [15328518.001]
  • [Cites] J Neurooncol. 1993 May;16(2):93-104 [7507162.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):19-27 [12532415.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Dec;22(6):429-37 [11147296.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):332-5 [12902879.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):490 [15717407.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):254-64 [8617201.001]
  • [Cites] Jpn J Cancer Res. 2002 Nov;93(11):1250-7 [12460467.001]
  • [Cites] J Neuroimmunol. 1993 Oct;48(1):71-9 [8227309.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5813-7 [12384543.001]
  • [Cites] Br J Cancer. 1993 Dec;68(6):1140-5 [7903153.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 1999 Jul-Aug;21(6):391-3 [10445230.001]
  • [Cites] J Neuroimmunol. 1994 Jan;49(1-2):19-24 [8294556.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):13-28 [9266437.001]
  • (PMID = 16200345.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


31. Bayrakli F, Dinçer A, Sav A, Vardareli E, Peker S: Late brain stem radionecrosis seventeen years after fractionated radiotherapy. Turk Neurosurg; 2009 Apr;19(2):182-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The appearance of a new lesion several years after radiation treatment for a primary brain tumor may represent different kind of pathologies.
  • We present a 24-year-old patient who suffered from right-sided hemiparesis and ataxic gait with a history of an operation due to left frontoparieal grade II fibrillary astrocytoma and fractioned radiotherapy.
  • The leading diagnosis was high-grade glial tumor.
  • Tissue sampling for histopathological examination is mandatory for definite diagnosis and correct treatment of the disease.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Brain Stem / pathology. Radiation Injuries / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19431132.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


32. Zambelli A, Lilleri D, Baldanti F, Scelsi M, Villani L, Da Prada GA: Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma. BMC Cancer; 2005;5:109
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma.
  • BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a complication of solid organ and allogeneic hematopoietic stem cell transplantation (HSCT); following autologous HSCT only rare cases of PTLD have been reported.
  • Here, a case of Hodgkin's disease (HD), as unusual presentation of PTLD after autologous HSCT for malignant glioma is described.
  • CASE PRESENTATION: 60-years old man affected by cerebral anaplastic astrocytoma underwent subtotal neurosurgical excision and subsequent high-dose chemotherapy followed by autologous HSCT.
  • [MeSH-major] Glioma / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Hodgkin Disease / diagnosis. Lymphoproliferative Disorders / etiology. Transplantation, Homologous / adverse effects


33. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS, Li M: Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res; 2008 Nov 1;14(21):6996-7003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival.
  • PURPOSE: To characterize the expression of sphingosine kinase-1 (SPHK1) in human astrocytomas and to investigate the association between SPHK1 expression and progression of astrocytomas.
  • EXPERIMENTAL DESIGN: The expression of SPHK1 in normal human astrocytes, astrocytoma cell lines, and four pairs of matched astrocytoma tissues and their adjacent normal brain tissues were detected by quantitative reverse transcription-PCR and Western blot.
  • In addition, SPHK1 protein expression was examined in 243 cases of histologically characterized astrocytomas by immunohistochemistry.
  • RESULTS: SPHK1 in astrocytoma cell lines was elevated at both mRNA and protein levels, and the SPHK1 mRNA and protein were significantly up-regulated by up to 6.8- and 40-fold, respectively, in primary astrocytomas compared with those in the adjacent noncancerous brain tissues.
  • Immunohistochemical analysis showed that 100 of 243 (41.2%) paraffin-embedded archival astrocytoma biopsies exhibited high expression of SPHK1.
  • Statistical analysis suggested that the up-regulation of SPHK1 was significantly correlated with the histologic grade of astrocytoma (P=0.000) and that patients with high SPHK1 level exhibited shorter survival time (P<0.001).
  • Multivariate analysis revealed that SPHK1 up-regulation might be an independent prognostic indicator for the survival of patients with astrocytoma.
  • CONCLUSIONS: SPHK1 might represent a novel and useful prognostic marker for astrocytoma and play a role during the development and progression of the disease.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / mortality. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Phosphotransferases (Alcohol Group Acceptor) / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease Progression. Female. Gene Expression. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980995.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase
  •  go-up   go-down


34. Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP: Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res; 2008 Nov 01;68(21):8673-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.
  • Brain tumors are the most common solid tumors of childhood, and pilocytic astrocytomas (PA) are the most common central nervous system tumor in 5 to 19 year olds.
  • This rearrangement, which was not observed in a series of 244 higher-grade astrocytomas, results in an in-frame fusion gene incorporating the kinase domain of the BRAF oncogene.
  • This is the first report of BRAF activation through rearrangement as a frequent feature in a sporadic tumor.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Duplication. Gene Fusion. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2002 Mar;12(3):458-61 [11875034.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):239-43 [9107428.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):94-101 [15630448.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):16244-53 [15710605.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Invest Dermatol. 2007 Jun;127(6):1468-70 [17301836.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Oncogene. 2008 May 15;27(22):3122-33 [18071315.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):722-9 [18438408.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • (PMID = 18974108.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2577184; NLM/ UKMS2350
  •  go-up   go-down


35. Diwan R, Jain B, Kapoor N: Assessment of prognosis of astrocytoma: is reticulin stain helpful? Indian J Pathol Microbiol; 2006 Jul;49(3):472-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of prognosis of astrocytoma: is reticulin stain helpful?
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Reticulin / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001928.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Reticulin
  •  go-up   go-down


36. Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, Leonard JR, Watson MA, Gutmann DH, Nagarajan R: High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene; 2008 Aug 7;27(34):4745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas.
  • Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors.
  • Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms.
  • Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus.
  • Furthermore, overexpression of wild-type HIPK2, but not a kinase-inactive mutant, in a glioma cell line conferred a growth advantage in vitro.
  • Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth.
  • [MeSH-major] Astrocytoma / genetics. Carrier Proteins / genetics. Cerebellar Neoplasms / genetics. Gene Amplification. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adolescent. Case-Control Studies. Child. Child, Preschool. Cluster Analysis. DNA Mutational Analysis / instrumentation. DNA Mutational Analysis / methods. Female. Gene Expression Regulation, Neoplastic. Gene Frequency. Humans. Male. Polymorphism, Single Nucleotide. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408760.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; EC 2.7.1.- / HIPK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


37. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR: Neurofibromatosis type 2. Lancet; 2009 Jun 6;373(9679):1974-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Half of patients inherit a germline mutation from an affected parent and the remainder acquire a de novo mutation for neurofibromatosis type 2.
  • Patients develop nervous system tumours (schwannomas, meningiomas, ependymomas, astrocytomas, and neurofibromas), peripheral neuropathy, ophthalmological lesions (cataracts, epiretinal membranes, and retinal hamartomas), and cutaneous lesions (skin tumours).
  • Optimum treatment is multidisciplinary because of the complexities associated with management of the multiple, progressive, and protean lesions associated with the disorder.
  • [MeSH-minor] Cataract / etiology. Chromosomes, Human, Pair 22 / genetics. Disease Progression. Gene Frequency / genetics. Genes, Neurofibromatosis 2. Genetic Testing. Humans. Molecular Biology. Mutation / genetics. Nervous System Neoplasms / etiology. Neurofibromin 2 / genetics. Patient Care Team / organization & administration. Pedigree. Penetrance. Peripheral Nervous System Diseases / etiology. Skin Neoplasms / etiology. Survival Rate


38. Kostic A, Mihailovic D, Veselinovic S, Tasic G, Radulovic D, Stefanovic I: Peritumoral edema and karyometric variables in astrocytoma of the brain. J BUON; 2007 Apr-Jun;12(2):239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral edema and karyometric variables in astrocytoma of the brain.
  • PURPOSE: The aim of this study was to evaluate karyometry as a quantitative and objective histological method by showing correlation of some karyometric variables with the severity of peritumoral edema in patients with brain astrocytoma.
  • The patients were diagnosed with astrocytoma of the brain, histologically confirmed on the surgically removed material.
  • Maximal tumor excision was performed in all patients, who were postoperatively treated according to current oncologic therapeutic protocols.
  • The intensity of perifocal edema (preoperative CT scan) was correlated to the duration of survival and the values of 9 karyometric tumor variables: area, density, maximal axis, mean axis, circumference, roundness, integrated optical density and number of nuclei.
  • Correlation of karyometric variables with CT findings revealed that higher degrees of tumor cellularity and nuclear wrinkling with increased integrated optical density is associated with larger peritumoral edema.
  • [MeSH-major] Astrocytoma / pathology. Brain Edema / pathology. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600879.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


39. Hao J, Zou X, Wilson MP, Davies NP, Sun Y, Peet AC, Arvanitis TN: A comparative study of feature extraction and blind source separation of independent component analysis (ICA) on childhood brain tumour 1H magnetic resonance spectra. NMR Biomed; 2009 Oct;22(8):809-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Short echo time (TE 30 ms), low and high field (1.5 and 3 T) in vivo brain tumour MR spectra of childhood astrocytoma, ependymoma and medulloblastoma were generated by using a quantum mechanical simulator with ten metabolite and lipid components.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19431141.001).
  • [ISSN] 1099-1492
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10342; United Kingdom / Medical Research Council / / G0601327; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Lipids
  •  go-up   go-down


40. Dreses-Werringloer U, Gérard HC, Whittum-Hudson JA, Hudson AP: Chlamydophila (Chlamydia) pneumoniae infection of human astrocytes and microglia in culture displays an active, rather than a persistent, phenotype. Am J Med Sci; 2006 Oct;332(4):168-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The intracellular pathogen Chlamydia pneumoniae can cause persistent infections during which its morphologic, molecular, and pathogenic characteristics differ importantly from those of active infection.
  • This bacterium was identified within astrocytes and microglia in the brain of late-onset Alzheimer disease patients.
  • METHODS: The human astrocytoma and microglioma cell lines U-87 MG and CHME-5 (respectively) and the human epithelial cell line HEp-2 were infected by the standard method with C pneumoniae strain AR-39.
  • [MeSH-minor] Cell Cycle / genetics. Cell Line, Tumor. Gene Expression Regulation, Bacterial. Genes, Bacterial. Humans. Organ Specificity. RNA, Bacterial / biosynthesis. RNA, Bacterial / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Virulence

  • Genetic Alliance. consumer health - Chlamydia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031241.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-44055; United States / NIAMS NIH HHS / AR / AR-44493; United States / NIAMS NIH HHS / AR / AR-47186
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / RNA, Bacterial; 0 / RNA, Messenger
  •  go-up   go-down


41. Dong L, Witkowski CM, Craig MM, Greenwade MM, Joseph KL: Cytotoxicity effects of different surfactant molecules conjugated to carbon nanotubes on human astrocytoma cells. Nanoscale Res Lett; 2009;4(12):1517-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity effects of different surfactant molecules conjugated to carbon nanotubes on human astrocytoma cells.
  • Phase contrast and epifluorescence microscopy were utilized to monitor morphological changes in human astrocytoma cells during a time-course exposure to single-walled carbon nanotube (SWCNT) conjugates with different surfactants and to investigate sub-cellular distribution of the nanotube conjugates, respectively.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Nanotechnol. 2007 Jan;2(1):47-52 [18654207.001]
  • [Cites] Exp Mol Pathol. 2009 Jun;86(3):215-23 [19186176.001]
  • [Cites] Bioorg Med Chem. 2009 Apr 15;17(8):2950-62 [19299149.001]
  • [Cites] J Pharm Sci. 1998 Nov;87(11):1305-7 [9811481.001]
  • [Cites] J Phys Chem B. 2005 Jul 14;109(27):13148-53 [16852637.001]
  • [Cites] Mol Pharm. 2004 Nov-Dec;1(6):399-405 [16028351.001]
  • [Cites] Nat Nanotechnol. 2006 Oct;1(1):60-5 [18654143.001]
  • [Cites] Cell Tissue Res. 2009 Jan;335(1):75-96 [18633647.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3357-62 [16492781.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):260-7 [16388306.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):41-53 [16371949.001]
  • [Cites] J Am Chem Soc. 2005 Apr 27;127(16):6021-6 [15839702.001]
  • [Cites] Environ Sci Technol. 2005 Mar 1;39(5):1378-83 [15787380.001]
  • [Cites] J Am Chem Soc. 2004 Dec 8;126(48):15638-9 [15571374.001]
  • [Cites] J Am Chem Soc. 2004 Jun 9;126(22):6850-1 [15174838.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1166-70 [14520401.001]
  • [Cites] Toxicol Sci. 2004 Jan;77(1):117-25 [14514968.001]
  • [Cites] Toxicol Sci. 2004 Jan;77(1):126-34 [14514958.001]
  • [Cites] Bioessays. 2003 Sep;25(9):888-96 [12938178.001]
  • [Cites] Toxicol Lett. 2006 Aug 1;165(1):88-100 [16527436.001]
  • [Cites] Science. 2002 Jul 26;297(5581):593-6 [12142535.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 23;47(1):65-81 [11251246.001]
  • [Cites] Annu Rev Physiol. 2001;63:795-813 [11181976.001]
  • [Cites] Science. 2003 May 2;300(5620):775-8 [12730595.001]
  • (PMID = 20652100.001).
  • [ISSN] 1931-7573
  • [Journal-full-title] Nanoscale research letters
  • [ISO-abbreviation] Nanoscale Res Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Astrocytoma cells / Blood–brain barrier / Brain tumors / Carbon nanotubes / Central nervous system / Cytotoxicity / Gene therapy / Non-viral gene vector / Surfactants
  •  go-up   go-down


42. Wu PS, Yao WJ: F-18 FDG PET in spinal cord pilocytic astrocytoma. Clin Nucl Med; 2010 Aug;35(8):649-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET in spinal cord pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Spinal Cord Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631528.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Hwang SL, Chang JH, Cheng TS, Sy WD, Lieu AS, Lin CL, Lee KS, Howng SL, Hong YR: Expression of Rac3 in human brain tumors. J Clin Neurosci; 2005 Jun;12(5):571-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rac3 may play an important role in tumor growth but little is known about its expression and mutation in human tumor tissues.
  • Overexpression of the Rac3 gene occurred in 19% (5/26) of brain tumors; 3 of 9 (33%) meningiomas, 1 of 11 (9%) astrocytomas and 1 of 6 (17%) pituitary adenomas.
  • The only astrocytoma with Rac3 overexpression was a glioblastoma multiforme.
  • Mutation of the Rac3 gene occurred in 63% (12/19) of brain tumours; 4 of 7 (57.1%) meningiomas, 4 of 5 (80%) pituitary adenomas and 4 of 7 (57.1%) astrocytomas.
  • Except in one astrocytoma, the other four tumors with Rac3 overexpression (3 meningiomas and one pituitary adenoma) did not have Rac3 mutations.
  • Overexpression may be associated with aggressive tumor behavior.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic / genetics. Mutation / genetics. rac GTP-Binding Proteins / genetics
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / metabolism. Chromosomes, Human, Pair 17 / genetics. DNA Mutational Analysis. GTP Phosphohydrolases / metabolism. Genetic Testing. Humans. Meningioma / diagnosis. Meningioma / genetics. Meningioma / metabolism. Neoplasm Invasiveness / genetics. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / genetics. Pituitary Neoplasms / metabolism. Predictive Value of Tests. RNA, Messenger / analysis. RNA, Messenger / genetics. Signal Transduction / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993075.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RAC3 protein, human; 0 / RNA, Messenger; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.5.2 / rac GTP-Binding Proteins
  •  go-up   go-down


44. Ghosal N, Furtado SV, Hegde AS: Rosette forming glioneuronal tumor pineal gland and tectum: an intraoperative diagnosis on smear preparation. Diagn Cytopathol; 2010 Aug;38(8):590-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosette forming glioneuronal tumor pineal gland and tectum: an intraoperative diagnosis on smear preparation.
  • We present an extremely rare case of newly described entity called rosette forming glioneuronal tumor (RGNT), involving the pineal gland, tectum, and the adjacent thalamus in a 22-year-old male.
  • The tumor was diagnosed intraoperatively on smear preparation on cytomorphology.
  • One of the components is pilocytic astrocytoma and the other is composed of small cells with scant cytoplasm, vesicular nuclei, arranged around neuropil-like material forming "neurocytic rosettes."
  • [MeSH-major] Brain Neoplasms / diagnosis. Cytological Techniques / methods. Glioma / diagnosis. Intraoperative Care. Pineal Gland / pathology. Rosette Formation. Tectum Mesencephali / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19941371.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Salvati M, D'Elia A, Melone GA, Brogna C, Frati A, Raco A, Delfini R: Radio-induced gliomas: 20-year experience and critical review of the pathology. J Neurooncol; 2008 Sep;89(2):169-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radio-induced gliomas: 20-year experience and critical review of the pathology.
  • The authors report their personal experience with a surgical series of 16 cases of cerebral radiation-induced gliomas, defining diagnostic criteria and surgical and clinical characteristics.
  • There were 14 cases of glioblastoma (grade IV WHO) and 2 cases of astrocytoma (grade II WHO), with a mean latency time of 17 years (range: 6-26 years).
  • [MeSH-major] Brain Neoplasms / etiology. Brain Neoplasms / pathology. Cranial Irradiation / adverse effects. Glioma / etiology. Glioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):176-80 [2485912.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):469-74 [2536806.001]
  • [Cites] Tumori. 1994 Jun 30;80(3):220-3 [8053080.001]
  • [Cites] Ann Neurol. 1978 Oct;4(4):319-21 [727737.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1431-8 [10329596.001]
  • [Cites] Cancer. 1979 Jun;43(6):2243-7 [222421.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Oct 20;289(6451):1038-9 [6435760.001]
  • [Cites] Transplant Proc. 1982 Dec;14(4):770-4 [6301119.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] No To Shinkei. 2000 May;52(5):413-8 [10845210.001]
  • [Cites] No Shinkei Geka. 2001 Jul;29(7):673-7 [11517510.001]
  • [Cites] Cancer. 1980 Apr 15;45(8):2051-5 [7370950.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9 [17882018.001]
  • [Cites] Cancer. 1978 Sep;42(3):1185-91 [100207.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1978 Nov;41(11):1005-12 [213536.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] J Neurosurg Sci. 1989 Jul-Sep;33(3):271-9 [2693630.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):886-94 [2424587.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1506-8 [3545441.001]
  • [Cites] Cancer. 1986 May 15;57(10):1979-85 [3006906.001]
  • [Cites] Neurosurg Rev. 2005 Jul;28(3):226-8 [15614578.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):392-7 [1845944.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):67-72 [2319293.001]
  • [Cites] Radiology. 1960 Jun;74:889-904 [14440717.001]
  • [Cites] Br J Radiol. 1985 May;58(689):480-2 [4063702.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 May;38(5):287-91 [9640965.001]
  • [Cites] No Shinkei Geka. 1995 Feb;23(2):151-5 [7877736.001]
  • [Cites] J Neurosurg. 1985 Feb;62(2):300-3 [3855445.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] Neurosurgery. 1988 Jun;22(6 Pt 1):1095-7 [3419575.001]
  • [Cites] Med J Aust. 1986 Jul 21;145(2):96-7 [3461240.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2563-6 [6266634.001]
  • [Cites] Childs Nerv Syst. 1988 Oct;4(5):296-301 [3072075.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):554-6 [2058514.001]
  • [Cites] Neurosurgery. 1991 Oct;29(4):606-8 [1658678.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):622-7 [632887.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):710-3 [11596968.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] Neurol India. 1999 Jun;47(2):142-4 [10402343.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1510-8 [3476182.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Neurosurg. 2001 May;94(5):816-21 [11354416.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1979 Fall;1(3):285-7 [317418.001]
  • [Cites] J Neurosurg. 1980 Jun;52(6):838-41 [7381543.001]
  • [Cites] Neurosurgery. 1987 Jul;21(1):33-8 [3614601.001]
  • [Cites] Neuroradiology. 1990;32(4):331-3 [2234396.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] Neurology. 1981 May;31(5):616-9 [7194977.001]
  • [Cites] Neurosurgery. 1980 May;6(5):546-51 [6251397.001]
  • [Cites] Neurol Med Chir (Tokyo). 1985 Jul;25(7):528-33 [2415845.001]
  • [Cites] Arch Environ Health. 1976 Jan-Feb;31(1):21-8 [1244805.001]
  • [Cites] Dtsch Med Wochenschr. 1979 Jul 6;104(27):969-72 [456271.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Childs Brain. 1982;9(1):1-9 [6277573.001]
  • [Cites] Can J Neurol Sci. 1984 Nov;11(4):475-8 [6518432.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Ann R Coll Surg Engl. 1960 Nov;27:310-54 [13790479.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Neurol Med Chir (Tokyo). 1977;17 (1 Pt 1):55-62 [74032.001]
  • [Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]
  • [Cites] Gynecol Oncol. 1982 Feb;13(1):108-14 [7060984.001]
  • [Cites] Neurosurgery. 1983 Jul;13(1):85-9 [6308498.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):445-9 [682008.001]
  • [Cites] Am J Public Health Nations Health. 1966 Dec;56(12):2114-20 [5334312.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • [Cites] Neurosurgery. 1986 Jul;19(1):114-9 [3018623.001]
  • (PMID = 18566750.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D: Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene; 2006 May 4;25(19):2818-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization.
  • Glioblastoma (GBM) is a highly malignant glioma, which has the propensity to infiltrate throughout the brain in contrast to pilocytic astrocytoma (PA) of the posterior fossa, which does not spread and can be cured by surgery.
  • We have used Suppression Subtractive Hybridization to define markers that better delineate the molecular basis of brain invasion and distinguish these tumor groups.
  • [MeSH-major] Astrocytoma / genetics. Gene Expression Profiling. Genes, Neoplasm / physiology. Glioblastoma / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Subtraction Technique

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314830.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


47. Seddighi AS, Seddighi A: Extramedullary hematopoiesis presenting as a compressive cord and cerebral lesion in a patient without a significant hematologic disorder: a case report. J Med Case Rep; 2010;4:319
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary hematopoiesis presenting as a compressive cord and cerebral lesion in a patient without a significant hematologic disorder: a case report.
  • Most of the reported cases are extradural lesions or, on rare occasions, foci within another neoplasm such as hemangioblastoma, meningioma or pilocytic astrocytoma.
  • Often these cases occur in patients with an underlying hematological disorder such as acute myelogenic leukemia, myelofibrosis, or other myelodysplastic syndromes.
  • CASE PRESENTATION: We report the case of a 43-year-old Iranian woman in whom extramedullary hematopoiesis presented as a compressive cord lesion and then later as an intracranial lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939863.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2972301
  •  go-up   go-down


48. Massimi L, Caldarelli M, D'Alessandris QG, Rollo M, Lauriola L, Giangaspero F, Di Rocco C: 12-year-old boy with multiple brain masses. Brain Pathol; 2010 May;20(3):679-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of more than one brain tumor in a single patient is not new, resulting from RT- or CT-induced neoplasms, syndromes or casual association.
  • We report on the exceptional case of a 12-year-old boy harboring three different brain tumors with no definite correlation.
  • The first MRI showed a medulloblastoma with signs of infratentorial and supratentorial tumor spreading, including a small frontal mass.
  • Finally, the possible local recurrence of the original medulloblastoma was a pilocytic astrocytoma with post-radiation alterations.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522094.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


49. Bahuleyan B, Daniel RT, Chacko G, Chacko AG: Epidermoid cysts of the velum interpositum. J Clin Neurosci; 2008 Oct;15(10):1159-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lesions located within the velum interpositum are rare and include meningiomas, pilocytic astrocytomas, atypical teratoid/rhabdoid tumors and arachnoid cysts.
  • [MeSH-major] Brain Diseases / pathology. Central Nervous System Cysts / pathology. Corpus Callosum / pathology. Epidermal Cyst / pathology. Pia Mater / pathology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18710812.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


50. Willems WF, Wieringa JW, Vermeulen RJ, Veenhoven RH: [Limping in toddlers due to disorders of the spine and spinal cord]. Ned Tijdschr Geneeskd; 2007 Oct 20;151(42):2297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Mank lopen bij peuters door afwijkingen aan de wervelkolom en het ruggenmerg.
  • The authors describe three cases of limping in toddlers caused by infrequent spinal diseases.
  • In the last patient, a 19-month-old girl, the limping was caused by an intraspinal intramedullary astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Bone Neoplasms / secondary. Discitis / diagnosis. Neuroblastoma / pathology. Spinal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064928.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


51. Chen KT, Lin JD, Liou MJ, Weng HF, Chang CA, Chan EC: An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines. Cancer Lett; 2006 Jan 18;231(2):192-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Platelet-derived growth factor receptor (PDGFR) can bind to its ligand and consequently possess a kinase activity, and which is associated with the carcinogenesis of different cell types, including astrocytomas, oligodendrogliomas, and glioblastoma.
  • [MeSH-minor] Blotting, Western. Cell Proliferation / drug effects. DNA, Complementary. Enzyme Activation. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. Phosphorylation. Platelet-Derived Growth Factor / genetics. Platelet-Derived Growth Factor / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tumor Cells, Cultured. Tyrosine / metabolism. Tyrphostins / pharmacology


52. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L: Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging; 2005 Jan;32(1):39-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
  • METHODS: Cerebral uptake of FDG and MET was determined sequentially on the same day in 30 patients (21 males, nine females; age 40.4+/-15.6 years), on average 4.0 years (range 0.1-18) after therapy for a primary brain tumour (23 grade II-IV astrocytomas, four oligodendrogliomas and three mixed oligo-astrocytomas).
  • The combination of FDG and MET information resulted in the highest prognostic accuracy (p=0.003), while MET alone was the best prognostic predictor in the subgroup of patients with primary astrocytoma (n=23).
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / mortality. Fluorodeoxyglucose F18. Glioma / diagnostic imaging. Glioma / mortality. Methionine. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / mortality

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Sep 15;92 (6):1541-9 [11745233.001]
  • [Cites] J Nucl Med. 1995 Mar;36(3):484-92 [7884515.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Jun;38(6):342-7; discussion 347-8 [9689817.001]
  • [Cites] Radiology. 2002 Nov;225(2):567-74 [12409596.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):608-15 [10682673.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):396-404 [11786566.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):542-50 [12507094.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Apr;16(2):187-98 [9101328.001]
  • [Cites] Neuroradiology. 2003 Jan;45(1):1-10 [12525947.001]
  • [Cites] J Appl Clin Med Phys. 2003 Winter;4(1):8-16 [12540814.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] Pediatr Neurosurg. 2003 Mar;38(3):146-55 [12601239.001]
  • [Cites] Eur J Nucl Med. 2001 Feb;28(2):165-74 [11303886.001]
  • [Cites] Neurology. 1996 Sep;47(3):684-90 [8797465.001]
  • [Cites] Acta Radiol. 1991 May;32(3):197-202 [2064862.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):23-7 [9443732.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1861-7 [11079496.001]
  • [Cites] J Nucl Med. 1997 May;38(5):802-8 [9170450.001]
  • [Cites] Eur J Nucl Med. 2001 Dec;28(12 ):1851-72 [11734927.001]
  • [Cites] J Neuroimaging. 1997 Jan;7(1):8-15 [9038426.001]
  • [Cites] J Nucl Med. 1997 Apr;38(4):517-22 [9098193.001]
  • [Cites] N Engl J Med. 2001 Jun 28;344(26):2030-1 [11430342.001]
  • [Cites] Neurosurgery. 2002 May;50(5):958-64; discussion 964-5 [11950398.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):115-26 [8988735.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 May;29(5):632-40 [11976801.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):855-61 [11504082.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;73(1-4):9-14 [10853090.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1098-106 [8780549.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):778-87 [10952489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54 [12377338.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1561-7 [14579097.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):205-12 [9935078.001]
  • [Cites] Radiographics. 1992 Mar;12 (2):269-79 [1561416.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] J Nucl Med. 1994 Jul;35(7):1104-9 [8014665.001]
  • (PMID = 15309329.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


53. Hon SF, Wong GK, Zhu XL, Ng HK, Sin NC, Poon WS: Surgical treatment of a neonate with refractory seizures secondary to congenital giant cell astrocytoma: case report and literature review. Hong Kong Med J; 2006 Jun;12(3):222-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of a neonate with refractory seizures secondary to congenital giant cell astrocytoma: case report and literature review.
  • Most congenital brain tumours are neuro-ectodermal tumours and medulloblastomas; giant cell astrocytoma and other tuberous sclerosis-related tumours are rare.
  • Surgical resection was performed successfully and pathology revealed the tumour to be a giant cell astrocytoma.

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760552.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Number-of-references] 8
  •  go-up   go-down


54. Gu S, Bao N, Yin MZ: Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature. J Child Neurol; 2010 Feb;25(2):216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature.
  • Desmoplastic infantile astrocytoma is a rare low-grade malignant brain tumor found in infants.
  • A case of desmoplastic infantile astrocytoma, including its clinical manifestations, pathological characteristics, differential diagnosis, treatment, and prognosis, is reported.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Cranial Fontanelles / surgery. Neurosurgical Procedures / methods


55. Soichi O, Masanori N, Hideo T, Kazunori A, Nobuya I, Jun-ichi K: Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. Neurosurgery; 2007 Apr;60(4):707-14; discussion 714
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: To determine whether or not ABCA2 can distinguish oligodendrogliomas from astrocytic tumors, the authors investigated the expression of ABCA2 in a panel of 55 glioma tissues (13 oligodendrogliomas, nine anaplastic oligodendrogliomas, 12 anaplastic astrocytomas, and 21 glioblastomas) using real-time reverse-transcriptase polymerase chain reaction analysis, immunoblot analysis, and immunohistochemistry analysis.
  • RESULTS: The relative expression level of ABCA2 messenger ribonucleic acid determined by real-time quantitative polymerase chain reaction is significantly higher (by a factor of five) in oligodendroglioma than in anaplastic astrocytoma or glioblastoma.
  • In immunohistochemical analysis, ABCA2 exhibited remarkable immunopositivity in 11 out of 13 oligodendrogliomas showing a granular pattern in the cytoplasm of tumor cells.
  • However, ABCA2 was completely negative in most anaplastic astrocytomas (75%) and glioblastomas (76%).
  • However, Olig2 was strongly positive in most anaplastic astrocytomas (83%) and glioblastomas (71%).
  • Although there was no difference in the detection of oligodendroglial tumors, the specificity (negative in astrocytic tumor) was significantly higher in ABCA2 than in Olig2.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Neoplasm Proteins / metabolism. Oligodendroglioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415208.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCA2 protein, human; 0 / ATP-Binding Cassette Transporters; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


56. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP: CpG island hypermethylation in human astrocytomas. Cancer Res; 2010 Apr 1;70(7):2718-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG island hypermethylation in human astrocytomas.
  • Astrocytomas are common and lethal human brain tumors.
  • We have analyzed the methylation status of over 28,000 CpG islands and 18,000 promoters in normal human brain and in astrocytomas of various grades using the methylated CpG island recovery assay.
  • In astrocytomas, several hundred CpG islands undergo specific hypermethylation relative to normal brain with 428 methylation peaks common to more than 25% of the tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] PLoS Genet. 2007 Oct;3(10):2023-36 [17967063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):252-7 [18162535.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):358-65 [17653095.001]
  • [Cites] PLoS Biol. 2008 Jan;6(1):e22 [18232738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12979-84 [18753622.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Methods Mol Biol. 2009;507:65-75 [18987807.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):671-8 [19139413.001]
  • [Cites] Nat Biotechnol. 2009 Apr;27(4):361-8 [19329998.001]
  • [Cites] Epigenetics. 2009 Feb 16;4(2):107-13 [19276669.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):181-7 [19429482.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):188-97 [19429483.001]
  • [Cites] Breast Cancer Res. 2009;11(1):R14 [19250546.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):514-26 [19477430.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Sep;48(9):828-41 [19530241.001]
  • [Cites] Epigenetics. 2009 May 16;4(4):255-64 [19550145.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7124-9 [19934302.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):345-55 [19353266.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Genomics. 2002 Nov;80(5):487-98 [12408966.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):52-9 [12794756.001]
  • [Cites] BMC Cancer. 2004 Sep 14;4:65 [15367334.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2265-74 [16079250.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):35-40 [16466990.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6665-74 [16818640.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7939-47 [16912168.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8469-76 [16951158.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1378-85 [17072317.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • (PMID = 20233874.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084469-10A1; United States / NCI NIH HHS / CA / R01 CA084469; United States / NCI NIH HHS / CA / CA084469; United States / NCI NIH HHS / CA / R01 CA084469-10A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS176198; NLM/ PMC2848870
  •  go-up   go-down


57. Mallur PS, Wisoff JH, Lalwani AK: Steroid responsive fluctuating sensorineural hearing loss due to juvenile pilocytic astrocytoma involving the cerebellopontine angle. Int J Pediatr Otorhinolaryngol; 2008 Apr;72(4):529-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid responsive fluctuating sensorineural hearing loss due to juvenile pilocytic astrocytoma involving the cerebellopontine angle.
  • We report on a rare case of an intrinsic brainstem neoplasm presenting with steroid responsive fluctuating sensorineural hearing loss in a child.
  • Magnetic resonance imaging with contrast enhancement revealed an intrinsic neoplasm of the middle cerebellar peduncle impinging on the 7th/8th neurovascular bundle within the CPA.
  • The patient underwent gross total resection of the juvenile pilocytic astrocytoma via retrosigmoid craniotomy and remains disease free at 2 years postoperatively.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Cerebellopontine Angle / pathology. Hearing Loss, Sensorineural / drug therapy. Hearing Loss, Sensorineural / etiology


58. Spadaro E, Migliacci ML, Romano LM, Zoppi J: [Astrocytoma grade II. Atypical image]. Medicina (B Aires); 2008;68(4):305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Astrocytoma grade II. Atypical image].
  • [Transliterated title] Astrocitoma grado II. Imagen atípica.
  • [MeSH-major] Astrocytoma / pathology. Brain / pathology. Brain Neoplasms / pathology. Demyelinating Diseases / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786888.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


59. Souweidane MM, Morgenstern PF, Christos PJ, Edgar MA, Khakoo Y, Rutka JT, Dunkel IJ: Intraoperative arachnoid and cerebrospinal fluid sampling in children with posterior fossa brain tumors. Neurosurgery; 2009 Jul;65(1):72-8; discussion 78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Arachnoid tissue and CSF from the cisterna magna (CSFCM) was sampled at the time of primary tumor resection.
  • Arachnoid infiltration and CSF cytology were found in 20.0% and 44.8%, respectively, for medulloblastoma/pineoblastoma (primitive neuroectodermal tumor), 6.9% and 3.6% for pilocytic astrocytoma, and 0.0% and 33.3% for ependymoma.
  • The 3-year EFS for patients with primitive neuroectodermal tumor who had positive arachnoid sampling was 33.3%, compared with 67.3% in patients who had no evidence of arachnoid infiltration (P = 0.26).
  • The 3-year EFS for patients with primitive neuroectodermal tumor who had positive CSFCM was 50.0% compared with 67.5% in patients who had negative cytological analysis of CSFCM (P = 0.07).
  • CONCLUSION: Intraoperative evidence of arachnoid infiltration or CSFCM dissemination in patients with posterior fossa brain tumors occurs at a variable frequency that is dependent on tumor type, correlates with conventional M stage, and may be predictive of outcome.
  • [MeSH-major] Arachnoid / surgery. Astrocytoma. Infratentorial Neoplasms

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574827.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Mueller S, Chang S: Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics; 2009 Jul;6(3):570-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article will outline current and future therapeutic strategies for the most common pediatric CNS tumors, including primitive neuroectodermal tumors such as medulloblastoma, as well as astrocytomas and ependymomas.
  • [MeSH-minor] Animals. Astrocytoma / therapy. Child, Preschool. Clinical Trials as Topic. Drug Therapy / methods. Ependymoma / physiopathology. Ependymoma / therapy. Glioma / therapy. Humans. Medulloblastoma / therapy. Neoplasm Staging. Neurosurgical Procedures / methods. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560746.001).
  • [ISSN] 1933-7213
  • [Journal-full-title] Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  • [ISO-abbreviation] Neurotherapeutics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 172
  •  go-up   go-down


61. Ide T, Miyoshi N, Ochiai K, Yasuda N: Oligoastrocytoma of the brain in a hooded crane (Grus monacha). Vet Pathol; 2009 Mar;46(2):309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cerebral tumor was identified at necropsy in a mature female hooded crane (Grus monacha).
  • On gross examination, the cut surface of the tumor revealed a soft gelatinous mass.
  • On histologic examination, the tumor was mainly composed of 2 discrete components that resembled oligodendroglioma and astrocytoma.
  • Based on these findings, the tumor was diagnosed as an oligoastrocytoma.
  • [MeSH-major] Astrocytoma / veterinary. Bird Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261644.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Huber JF, Bradley K, Spiegler BJ, Dennis M: Long-term effects of transient cerebellar mutism after cerebellar astrocytoma or medulloblastoma tumor resection in childhood. Childs Nerv Syst; 2006 Feb;22(2):132-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of transient cerebellar mutism after cerebellar astrocytoma or medulloblastoma tumor resection in childhood.
  • BACKGROUND: Following cerebellar tumor resection, some patients develop transient cerebellar mutism (TCM).
  • RESULTS: Tumor survivors who had TCM had significantly more ataxic dysarthric speech and slower speech than either those without TCM or controls and were more dysfluent than controls.
  • Tumor survivors without TCM did not differ from controls on ataxic dysarthria or speech rate.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Medulloblastoma / surgery. Mutism / etiology. Postoperative Complications

  • Genetic Alliance. consumer health - Cerebellar Astrocytoma, Childhood.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2007 May;23(5):477 [17384951.001]
  • [Cites] Int J Neurol. 1970;7(2):302-18 [5499525.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):91-101 [8817420.001]
  • [Cites] Neuroradiology. 1995 Feb;37(2):104-8 [7760992.001]
  • [Cites] Brain Lang. 2002 Mar;80(3):592-602 [11896659.001]
  • [Cites] Pediatr Neurosurg. 2003 Oct;39(4):179-83 [12944697.001]
  • [Cites] Dev Med Child Neurol. 1992 Dec;34(12 ):1102-9 [1451941.001]
  • [Cites] Pediatr Neurol. 1997 Apr;16(3):218-9 [9165512.001]
  • [Cites] Brain. 2000 Oct;123 ( Pt 10):1985-2004 [11004117.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Neurology. 1994 Nov;44(11):2040-6 [7969956.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):13-21 [8988076.001]
  • [Cites] Pediatr Rehabil. 1997 Jan-Mar;1(1):41-4 [9689237.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):60-5;discussion 66 [8747952.001]
  • [Cites] J Speech Hear Res. 1979 Sep;22(3):627-48 [502519.001]
  • [Cites] J Speech Hear Res. 1969 Sep;12(3):462-96 [5811846.001]
  • [Cites] Neurosurgery. 1995 Nov;37(5):894-8 [8559337.001]
  • [Cites] Neurosurgery. 1995 Nov;37(5):885-93 [8559336.001]
  • [Cites] J Speech Hear Res. 1969 Jun;12(2):246-69 [5808852.001]
  • [Cites] Brain. 2000 May;123 ( Pt 5):1051-61 [10775549.001]
  • [Cites] Childs Nerv Syst. 1998 Apr-May;14(4-5):161-6 [9660116.001]
  • [Cites] Childs Nerv Syst. 1989 Feb;5(1):12-4 [2649239.001]
  • [Cites] J Child Neurol. 2007 Jul;22(7):848-54 [17715277.001]
  • [Cites] Arch Neurol. 1985 Jul;42(7):697-8 [4015467.001]
  • [Cites] J Neurosurg. 1990 Jun;72 (6):959-63 [2187060.001]
  • (PMID = 16155765.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD 35946
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


63. Mezer E, Nischal KK, Nahjawan N, MacKeen LD, Buncic JR: Hemifacial spasm as the initial manifestation of childhood cerebellar astrocytoma. J AAPOS; 2006 Oct;10(5):489-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemifacial spasm as the initial manifestation of childhood cerebellar astrocytoma.

  • Genetic Alliance. consumer health - Cerebellar Astrocytoma, Childhood.
  • Genetic Alliance. consumer health - Hemifacial Spasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070492.001).
  • [ISSN] 1091-8531
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Shah MN, Leonard JR, Perry A: Rosette-forming glioneuronal tumors of the posterior fossa. J Neurosurg Pediatr; 2010 Jan;5(1):98-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare, recently described WHO Grade I neoplasm.
  • The original diagnoses included pilocytic astrocytoma, ependymoma, cerebellar dysembryoplastic neuroepithelial tumor (DNT), and oligodendroglioma.
  • These cases expand the known clinical and histological spectrum of this rare tumor type.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / surgery. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Cranial Fossa, Posterior. Ependymoma / diagnosis. Ependymoma / surgery. Magnetic Resonance Imaging. Neuroectodermal Tumors, Primitive / diagnosis. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043744.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Alimohamadi M, Bidabadi MS, Ayan Z, Ketabchi E, Amirjamshidi A: Pilomyxoid astrocytoma with involvement of the sella turcica in an adolescent. J Clin Neurosci; 2009 Dec;16(12):1648-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma with involvement of the sella turcica in an adolescent.
  • Pilomyxoid astrocytoma (PMA) is a recently described tumor typically occurring in the hypothalamic-chiasmatic region of very young children.
  • PMA is characterized by a more aggressive course than pilocytic astrocytoma and exhibits certain differing histological features.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Sella Turcica / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766001.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


66. Mano Y, Kanamori M, Sonoda Y, Kumabe T, Watanabe M, Tominaga T: [A case report of cerebellar pleomorphic xanthoastrocytoma]. No Shinkei Geka; 2009 Jun;37(6):586-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) is a type of astrocytic neoplasm, classified as WHO grade II, which mainly occurs supratentorially, and rarely infratentorially.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522287.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


67. Lehman NL: Central nervous system tumors with ependymal features: a broadened spectrum of primarily ependymal differentiation? J Neuropathol Exp Neurol; 2008 Mar;67(3):177-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several other CNS tumor entities, including astroblastoma, chordoid glioma, papillary tumor of the pineal region, angiocentric glioma, and pilomyxoid astrocytoma, variably display histopathologic features of ependymal differentiation.
  • These issues are addressed in the context of early morphologic insights of Bailey and Cushing, Friede, and others; contemporary oncologic concepts; and recent relevant molecular and tumor stem cell studies.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344909.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS45077
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 81
  •  go-up   go-down


68. Baron PW, Majlessipour F, Bedros AA, Zuppan CW, Ben-Youssef R, Yanni G, Ojogho ON, Concepcion W: Undifferentiated embryonal sarcoma of the liver successfully treated with chemotherapy and liver resection. J Gastrointest Surg; 2007 Jan;11(1):73-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Undifferentiated embryonal sarcoma is the third most common malignant tumor of the liver in children, accounting for 13% of hepatic malignancies in this age group.
  • It has been considered an aggressive neoplasm with very poor prognosis until the late 1980s, when long-term survivors were reported after multiagent chemotherapy followed by resection.
  • The first patient also had a concurrent cerebellar tumor (pilocytic astrocytoma), for which he first underwent craniotomy and resection, delaying the liver tumor resection by 10 weeks.
  • They are alive and tumor free at 48 months (case no. 1) and 18 months (case no. 2) following neoadjuvant chemotherapy and liver resection.

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1992;22(5):451-5 [1421867.001]
  • [Cites] Cancer. 1993 Oct 15;72 (8):2511-6 [8402469.001]
  • [Cites] Med Pediatr Oncol. 1993;21(9):634-9 [8412995.001]
  • [Cites] Cancer. 1978 Jul;42(1):336-48 [208754.001]
  • [Cites] Med Pediatr Oncol. 1988;16(1):62-5 [3340065.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):512-37 [6303939.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):396-402 [3791152.001]
  • [Cites] Hum Pathol. 1990 Jan;21(1):68-76 [2403976.001]
  • [Cites] J Pediatr Surg. 1982 Feb;17(1):70-2 [7077481.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):252-7 [11815984.001]
  • [Cites] Presse Med. 1998 Mar 21;27(11):518-20 [9767962.001]
  • (PMID = 17390190.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Kim SY, Jung SH, Kim HS: Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem Biophys Res Commun; 2005 Nov 18;337(2):510-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells.
  • The abnormal expression of matrix metalloproteinases (MMPs) plays an important role in the invasion of malignant gliomas into the surrounding normal brain tissue.
  • This study showed that curcumin has broad-spectrum inhibitory activity against MMP gene expression in human astroglioma cells.
  • Curcumin was also found to significantly repress the in vitro invasion of glioma cells.
  • Therefore, the broad-spectrum inhibition of MMP gene expression by curcumin might provide a novel therapeutic strategy for treating gliomas.
  • [MeSH-major] Astrocytoma / enzymology. Curcumin / pharmacology. Enzyme Inhibitors / pharmacology. Matrix Metalloproteinase Inhibitors. Tissue Inhibitor of Metalloproteinase-3 / metabolism
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Base Sequence. Brain Neoplasms / pathology. Gene Expression. Glioma / drug therapy. Humans. Matrix Metalloproteinases / genetics. Mitogen-Activated Protein Kinases / metabolism. Ribonucleases / metabolism. Tissue Inhibitor of Metalloproteinase-1 / genetics. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Transcription Factor AP-1 / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198311.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Transcription Factor AP-1; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.1.- / Ribonucleases; EC 3.4.24.- / Matrix Metalloproteinases; IT942ZTH98 / Curcumin
  •  go-up   go-down


70. Bucci B, Misiti S, Cannizzaro A, Marchese R, Raza GH, Miceli R, Stigliano A, Amendola D, Monti O, Biancolella M, Amati F, Novelli G, Vecchione A, Brunetti E, De Paula U: Fractionated ionizing radiation exposure induces apoptosis through caspase-3 activation and reactive oxygen species generation. Anticancer Res; 2006 Nov-Dec;26(6B):4549-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, post-operative RT is considered the standard treatment adjuvant to surgery since its ability to prolong median survival of patients with malignant astrocytoma has been shown; nevertheless the ionizing radiation (IR) treatment fails in a considerable number of astrocytoma patients.
  • MATERIALS AND METHODS: Using an ADF human astrocytoma cell line the molecular mechanisms involved in the DNA damage induced by fractionated irradiation (FIR) and single IR treatment have been investigated.
  • RESULTS: FIR and single IR treatment inhibited the growth of the ADF human astrocytoma cell line.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Caspase 3 / metabolism. Radiation, Ionizing. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Apoptosis. Blotting, Western. Cell Line, Tumor. Dose Fractionation. Enzyme Activation. Humans. Oligonucleotide Array Sequence Analysis


71. Le BH, Sandusky M: 81 year-old male with confusion and weakness. Brain Pathol; 2010 Jul;20(4):867-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma, the most common primary brain tumor, is a highly infiltrative, malignant astrocytic neoplasm that demonstrates a wide spectrum of morphologic heterogeneity.
  • Cases with a primitive neuroectodermal tumor (PNET)-like component are rare, but are being increasingly recognized and studied.
  • Recently, data from the largest case series studying malignant gliomas with a PNET-like component suggest that the primitive component likely arises from the malignant glial component.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626749.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


72. Vassilyadi M, Michaud J: Hydrocephalus as the initial presentation of a spinal cord astrocytoma associated with leptomeningeal spread. Pediatr Neurosurg; 2005 Jan-Feb;41(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrocephalus as the initial presentation of a spinal cord astrocytoma associated with leptomeningeal spread.
  • The enhancement was initially thought to be the result of a partially treated meningitis (child was previously on oral antibiotics for a presumed mycoplasma pneumonia).
  • The lesion was subtotally resected (70%) and diagnosed as an astrocytoma (mostly Kernohan grade 2 but with areas of grade 3).
  • Chemotherapy was administered and follow-up spine MRI at 2 months did not reveal any residual tumor, however, the leptomeningeal enhancement persisted.
  • This case illustrates how a spinal cord astrocytoma can metastasize via spinocranial dispersion and present early with hydrocephalus rather than myelopathy.
  • [MeSH-major] Astrocytoma / pathology. Hydrocephalus / etiology. Meningeal Neoplasms / complications. Meningeal Neoplasms / secondary. Neoplastic Cells, Circulating. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15886510.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


73. Wilson PE, Oleszek JL, Clayton GH: Pediatric spinal cord tumors and masses. J Spinal Cord Med; 2007;30 Suppl 1:S15-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study presents detailed information regarding clinical presentation, histological findings, outcomes, functional assessment, and management of a series of patients with this diagnosis.
  • SUBJECTS: Thirty-five children with a final diagnosis of spinal cord tumor or mass, excluding dysraphism.
  • RESULTS: Neurodevelopmental tumors (dermoid tumors, epidermoid tumors, and teratomas) were the most common tumor type (31%), followed by astrocytomas (29%) and neuroblastomas (14%).
  • Mean age at diagnosis was 6.6 years (SD = 5.5 y) and did not vary significantly by tumor type except for children with neuroblastoma (mean = 0.4 y, SD = 0.5 y).
  • More boys (57%) were identified in the series than girls (43%); however, there was no association between tumor type and sex.
  • CONCLUSIONS: This study corroborates other studies indicating that intramedullary tumors are the predominant form of pediatric spinal cord tumor.
  • The predominance of astrocytomas and neuroblastomas among those patients with poor outcomes and the prevalence of developmental tumors suggest the need for broader investigation.
  • Although, in general, spinal cord tumors are relatively rare, this preliminary study supports the need to further evaluate associations between tumor type, presenting symptoms, treatment, and functional outcome in children with spinal cord tumors.
  • [MeSH-minor] Astrocytoma. Child. Child, Preschool. Female. Humans. Infant. Male. Meningioma. Neurilemmoma. Neuroblastoma. Retrospective Studies. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:550-89 [10800501.001]
  • [Cites] Neurosurg Focus. 2001;10(1):e3 [16749755.001]
  • [Cites] Pediatr Neurosurg. 2001 Sep;35(3):120-7 [11641619.001]
  • [Cites] Childs Nerv Syst. 2003 Sep;19(9):641-9 [12908118.001]
  • [Cites] Pediatr Neurosurg. 2004 Jan-Feb;40(1):16-22 [15007224.001]
  • [Cites] Semin Roentgenol. 2004 Jul;39(3):347-60 [15372749.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] J Neurosurg. 1967 Feb;26(2):276-82 [6019134.001]
  • [Cites] Clin Neurosurg. 1978;25:512-39 [568531.001]
  • [Cites] J Comput Assist Tomogr. 1981 Apr;5(2):274 [7217456.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1869-86 [2992750.001]
  • [Cites] Childs Nerv Syst. 1987;3(2):89-92 [3040249.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):523-32 [2319309.001]
  • [Cites] Neurosurg Clin N Am. 1992 Oct;3(4):931-45 [1392585.001]
  • [Cites] J Child Neurol. 1992 Oct;7(4):360-3 [1469242.001]
  • [Cites] Neurosurgery. 1994 Jul;35(1):69-74; discussion 74-6 [7936155.001]
  • [Cites] Int J Epidemiol. 1994 Jun;23(3):458-64 [7960369.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Feb 15;22(4):442-51 [9055374.001]
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):293-5 [9251736.001]
  • [Cites] Childs Nerv Syst. 1999 Jan;15(1):17-28 [10066016.001]
  • [Cites] Childs Nerv Syst. 1999 Sep;15(9):436-8 [10501998.001]
  • [Cites] Spinal Cord. 2005 Jan;43(1):34-41 [15326473.001]
  • [Cites] Neurosurg Focus. 2005 Feb 15;18(2):ECP1 [15715454.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):22-8 [15886509.001]
  • [Cites] Neurosurg Clin N Am. 2006 Jan;17(1):51-61 [16448908.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1129-43; discussion 1129-43 [16723892.001]
  • [Cites] J Neurooncol. 2000 May;47(3):225-30 [11016739.001]
  • (PMID = 17874681.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2031985
  •  go-up   go-down


74. Jang FF, Wei W, De WM: Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma. J Ayub Med Coll Abbottabad; 2008 Apr-Jun;20(2):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
  • BACKGROUND: Astrocytoma is the most malignant intracranial neoplasm and is characterized by high neovascularization and peritumoural brain oedema.
  • METHODS: The expression of two angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor were investigated using immunohistochemistry for astrocytoma from 82 patients and 11 normal human tissues.
  • RESULTS: The expression of vascular endothelial growth factor and basic fibroblast growth factor positively correlate with the pathological grade of astrocytoma, microvessel density numbers and brain oedema, which may be responsible for the increased tumour neovascularization and peritumoural brain oedema.
  • CONCLUSION: The results support the idea that inhibiting vascular endothelial growth factor and basic fibroblast growth factor are useful for the treatment of human astrocytoma and to improve patient's clinical outcomes and prognosis.
  • [MeSH-major] Astrocytoma / blood supply. Brain Edema / etiology. Brain Neoplasms / blood supply. Fibroblast Growth Factor 2 / biosynthesis. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385471.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


75. Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A: Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature. Neurol Res; 2009 Nov;31(9):931-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature.
  • OBJECTIVES: Survival and tumor recurrence for patients with low-grade gliomas is heterogeneous, with reported survival and recurrence times varying by several months to years.
  • The prognostic implications of a contrast-enhancing low-grade glioma remain less well understood.
  • METHODS: We retrospectively reviewed all adult patients who underwent a craniotomy for a hemispheric low-grade glioma (WHO grade II) from 1996 to 2006 at a single institution.
  • Furthermore, a review of the literature for all works on low-grade gliomas and contrast enhancement was conducted.
  • RESULTS: One hundred eighty-nine patients (87 fibrillary astrocytomas, 89 oligodendrogliomas and 13 mixed gliomas) were available for analysis, with 64 (34%) and 125 (66%) contrast-enhancing and non-enhancing tumors, respectively.
  • The majority of these published works had design-related limitations including small population size as well as the inclusion of non-WHO grade II gliomas, pediatric patients and patient undergoing biopsy.
  • DISCUSSION: This study may provide insights into risk stratifying patients with low-grade gliomas and most specifically those that contrast enhance.
  • [MeSH-major] Brain Neoplasms / pathology. Contrast Media. Glioma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Astrocytoma / epidemiology. Astrocytoma / pathology. Craniotomy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Predictive Value of Tests. Prognosis. Retrospective Studies. Sensitivity and Specificity. Severity of Illness Index. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215664.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


76. Essig M, Giesel F, Stieltjes B, Weber MA: [Functional imaging for brain tumors (perfusion, DTI and MR spectroscopy)]. Radiologe; 2007 Jun;47(6):513-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cases of brain tumor, PWI aids in grading and better differentiation in diagnostics as well as for pre-therapeutic planning.
  • PWI allows better estimates of biological activity and aggressiveness in low grade brain tumors, and in the case of WHO grade II astrocytoma showing anaplasically transformed tumor areas, allows more rapid visu-alization and a better prediction of the course of the disease than conventional MRI diagnostics.
  • Diffusion imaging can be used for describing brain tumors, for evaluating contralateral involvement and the course of the nerve fibers near the tumor.
  • Diagnostic problems such as the differentiation between neoplastic and non-neoplastic lesions, grading cerebral glioma and distinguishing between primary brain tumors and metastases can be resolved.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiologe. 2005 Apr;45(4):327-39 [15800783.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1603-10 [11039338.001]
  • [Cites] Neuroradiology. 2006 Apr;48 Suppl 1:3-8 [16699847.001]
  • [Cites] Radiologe. 2004 Jul;44(7):723-32; quiz 733-4 [15241598.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]
  • [Cites] Radiology. 1994 Dec;193(3):637-41 [7972800.001]
  • [Cites] Rofo. 1999 Jul;171(1):38-43 [10464503.001]
  • [Cites] Radiologe. 2004 Jan;44(1):81-95; quiz 96-7 [14997867.001]
  • [Cites] Radiologe. 2004 Feb;44(2):164-73 [14991136.001]
  • [Cites] Neuroimage. 2006 Jun;31(2):531-42 [16478665.001]
  • [Cites] Radiologe. 2003 Aug;43(8):661-4 [14504767.001]
  • [Cites] Radiology. 1990 Nov;177(2):401-5 [2217776.001]
  • [Cites] Radiologe. 2002 Nov;42(11):909-15 [12458444.001]
  • [Cites] Radiologe. 2005 Jul;45(7):618-32 [15098092.001]
  • [Cites] Nervenarzt. 2005 Apr;76(4):403-17 [15349736.001]
  • (PMID = 17505814.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 21
  •  go-up   go-down


77. Borgwardt L, Højgaard L, Carstensen H, Laursen H, Nowak M, Thomsen C, Schmiegelow K: Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol; 2005 May 1;23(13):3030-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FDG uptake in tumors was semiquantitatively calculated by a region-of-interest-based tumor hotspot/brain index.
  • The choroid plexus papilloma (n = 1) and the pilocytic astrocytomas (n = 3) had a mean index of 3.26 (n = 38; r = 0.57; P < .01).
  • Digitally performed PET/MRI coregistration increased information on tumor characterization in 90% of cases.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860860.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


78. Misra A, Pellarin M, Nigro J, Smirnov I, Moore D, Lamborn KR, Pinkel D, Albertson DG, Feuerstein BG: Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res; 2005 Apr 15;11(8):2907-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma.
  • Alterations of DNA copy number are believed to be important indicators of tumor progression in human astrocytoma.
  • [MeSH-minor] Cell Line, Tumor. Chromosome Aberrations. Cluster Analysis. Humans. In Situ Hybridization, Fluorescence. Reproducibility of Results. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837741.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA85799; United States / NINDS NIH HHS / NS / NS40958; United States / NINDS NIH HHS / NS / NS42927
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


79. Waschbisch A, Fiebich BL, Akundi RS, Schmitz ML, Hoozemans JJ, Candelario-Jalil E, Virtainen N, Veerhuis R, Slawik H, Yrjänheikki J, Hüll M: Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem; 2006 Feb;96(3):680-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB.
  • Here we describe IL-1beta-induced EP3 receptor expression in human astrocytoma cells, primary astrocytes of rat and human origin and in rat brain.
  • The analysis of involved signal transduction pathways by pathway-specific inhibitors revealed an essential role of protein kinase C and nuclear factor-kappaB in astrocytic IL-1beta-induced EP3 synthesis.
  • This might play an important role in acute and chronic conditions such as cerebral ischemia, traumatic brain injury, HIV-encephalitis, Alzheimer's disease and prion diseases in which a marked up-regulation of IL-1beta is followed by a prolonged increase of PGE2 levels in the brain.
  • [MeSH-major] Astrocytoma / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Interleukin-1 / pharmacology. NF-kappa B / physiology. Protein Kinase C / physiology. Receptors, Prostaglandin E / metabolism
  • [MeSH-minor] Animals. Astrocytes / drug effects. Astrocytes / metabolism. Blotting, Northern / methods. Blotting, Western / methods. Cell Line, Tumor. Cell Survival / drug effects. Drug Interactions. Enzyme Inhibitors / pharmacology. Humans. Male. RNA, Messenger / biosynthesis. Rats. Rats, Wistar. Receptors, Prostaglandin E, EP3 Subtype. Reverse Transcriptase Polymerase Chain Reaction / methods. Time Factors

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405508.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Interleukin-1; 0 / NF-kappa B; 0 / PTGER3 protein, human; 0 / Ptger3 protein, rat; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP3 Subtype; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


80. Shirai K, Suzuki Y, Okamoto M, Wakatsuki M, Noda SE, Takahashi T, Ishiuchi S, Hasegawa M, Nakazato Y, Nakano T: Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res; 2010;51(5):589-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma.
  • World Health Organization (WHO) grade 3 glioma is one of the common brain tumors and has three main histological subtypes, including anaplastic astrocytoma (AA), anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO).
  • In this study, 68 patients with histologically proven WHO grade 3 glioma, consecutively received postoperative radiotherapy at the Gunma University Hospital, Japan, between 1983 and 2005, were investigated to assess the impact of histological subtype on the survival.
  • Univariate analysis showed that the histological subtype (P < 0.01) and extent of surgery (P < 0.01) were significant prognostic factors for survival.
  • Multivariate analysis demonstrated that histological subtype, age and extent of surgery were the significant independent variable for survival (P < 0.01, P < 0.01 and P = 0.04).
  • In our study, histological subtype was one of the most important prognostic factors of WHO grade 3 glioma.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Oligodendroglioma / radiotherapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20921826.001).
  • [ISSN] 1349-9157
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


81. Juric-Sekhar G, Zarkovic K, Waeg G, Cipak A, Zarkovic N: Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain. Tumori; 2009 Nov-Dec;95(6):762-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain.
  • The aim of this study was to evaluate the expression of HNE in 120 astrocytic and 40 ependymal tumors in relation to tumor type, grade of malignancy, angiogenesis, and presence of necrosis and apoptosis.
  • The incidence of HNE-immunopositive tumor cells increased with increasing grades of malignancy.
  • Significantly higher HNE expression was found in tumor cells of glioblastomas multiforme than in cells of pilocytic astrocytomas (P < 0.005), and in anaplastic ependymomas than in benign ependymomas (P < 0.01).
  • HNE-immunopositive tumor cells were distributed more diffusely than in perivascular locations (P < 0.05).
  • HNE was expressed in the endothelium of almost all tumor vessels, but its expression in the walls of the vessels was significantly higher in diffuse and anaplastic astrocytomas than in pilocytic astrocytomas and glioblastomas multiforme (P < 0.05).
  • The number of microvessels containing HNE in their endothelium and walls was significantly associated with the grade of malignancy in both astrocytic (P < 0.001) and ependymal tumors (P < 0.05), although microvessels in pilocytic astrocytomas were significantly more numerous (P < 0.05) than in diffuse astrocytomas.
  • CONCLUSIONS: LPO seems to be a common pathological process in astrocytic and ependymal glial tumors, proportional to the level of malignancy and neovascularization.
  • [MeSH-major] Aldehydes / analysis. Astrocytoma / chemistry. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Ependymoma / chemistry. Lipid Peroxidation. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210242.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Biomarkers, Tumor; 0 / Cross-Linking Reagents; 0 / Neoplasm Proteins; K1CVM13F96 / 4-hydroxy-2-nonenal
  •  go-up   go-down


82. Saito M, Hori M, Obara Y, Ohizumi Y, Ohkubo S, Nakahata N: Neurotrophic factor production in human astrocytoma cells by 2,5,6-tribromogramine via activation of epsilon isoform of protein kinase C. Eur J Pharm Sci; 2006 Jul;28(4):263-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurotrophic factor production in human astrocytoma cells by 2,5,6-tribromogramine via activation of epsilon isoform of protein kinase C.
  • When rat pheochromocytoma (PC-12) cells were cultivated in the medium of human astrocytoma cells (1321N1) treated with 2,5,6-tribromogramine, they differentiated to neuron-like cells possessing neurites, indicating that 2,5,6-tribromogramine released neurotrophic factors from 1321N1 cells.
  • [MeSH-major] Astrocytoma / enzymology. Indole Alkaloids / pharmacology. Nerve Growth Factors / metabolism. Protein Kinase C-epsilon / metabolism
  • [MeSH-minor] Animals. Cell Differentiation. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Indoles / pharmacology. Maleimides / pharmacology. Nerve Growth Factor / genetics. Nerve Growth Factor / metabolism. Neurons / drug effects. Neurons / pathology. Phosphatidylinositols / metabolism. Protein Kinase Inhibitors / pharmacology. Protein Transport / drug effects. RNA, Messenger / metabolism. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569497.001).
  • [ISSN] 0928-0987
  • [Journal-full-title] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • [ISO-abbreviation] Eur J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2,5,6-tribromogramine; 0 / Indole Alkaloids; 0 / Indoles; 0 / Maleimides; 0 / Nerve Growth Factors; 0 / Phosphatidylinositols; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 133052-90-1 / bisindolylmaleimide I; 9061-61-4 / Nerve Growth Factor; EC 2.7.11.13 / PRKCE protein, human; EC 2.7.11.13 / Protein Kinase C-epsilon
  •  go-up   go-down


83. D'Alimonte I, Ciccarelli R, Di Iorio P, Nargi E, Buccella S, Giuliani P, Rathbone MP, Jiang S, Caciagli F, Ballerini P: Activation of P2X(7) receptors stimulates the expression of P2Y(2) receptor mRNA in astrocytes cultured from rat brain. Int J Immunopathol Pharmacol; 2007 Apr-Jun;20(2):301-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, it has recently been found that in astrocytes and astrocytoma cells P2Y(2) sites can trigger neuroprotective pathways through the activation of several mechanisms, including the induction of genes for antiapoptotic factors, neurotrophins, growth factors and neuropeptides.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624242.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P2rx7 protein, rat; 0 / P2ry2 protein, rat; 0 / RNA, Messenger; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7; 0 / Receptors, Purinergic P2Y2; 4P5DXU1F8Q / 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


84. Madsen S, Hirschberg H: Photodynamic therapy and detection of high-grade gliomas. J Environ Pathol Toxicol Oncol; 2006;25(1-2):453-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy and detection of high-grade gliomas.
  • The first reported use of photodynamic therapy (PDT) for the treatment of high-grade gliomas occurred in 1981.
  • In the intervening years there have been relatively few clinical trials to investigate the efficacy of this therapeutic modality for the treatment of gliomas.
  • This is due, in part, to the rarity of the disease, and the ever growing list of novel therapies that PDT must compete against.
  • During the mid-1990s, a number of reviews were published that effectively summarized the status of PDT for the management of high-grade gliomas.
  • The intent of the present work is to provide an update of recent developments (1996-2004) in PDT and photodynamic detection (PDD) of gliomas, in particular, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA).
  • [MeSH-major] Glioma / diagnosis. Glioma / drug therapy. Photochemotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566735.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 73
  •  go-up   go-down


85. Righi V, Roda JM, Paz J, Mucci A, Tugnoli V, Rodriguez-Tarduchy G, Barrios L, Schenetti L, Cerdán S, García-Martín ML: 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed; 2009 Jul;22(6):629-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas.
  • We investigate the profile of choline metabolites and the expression of the genes of the Kennedy pathway in biopsies of human gliomas (n = 23) using (1)H High Resolution Magic Angle Spinning (HR-MAS, 11.7 Tesla, 277 K, 4000 Hz) and individual genetic assays. (1)H HR-MAS spectra allowed the resolution and relative quantification by the LCModel of the resonances from choline (Cho), phosphocholine (PC) and glycerophosphorylcholine (GPC), the three main components of the combined tCho peak observed in gliomas by in vivo (1)H NMR spectroscopy.
  • All glioma biopsies depicted a prominent tCho peak.
  • However, the relative contributions of Cho, PC, and GPC to tCho were different for low and high grade gliomas.
  • Whereas GPC is the main component in low grade gliomas, the high grade gliomas show a dominant contribution of PC.
  • This circumstance allowed the discrimination of high and low grade gliomas by (1)H HR-MAS, a result that could not be obtained using the tCho/Cr ratio commonly used by in vivo (1)H NMR spectroscopy.
  • High grade gliomas depict an upregulation of the beta gene of choline kinase and phospholipase C, as well as a downregulation of the cytidyltransferase B gene, the balance of these being consistent with the accumulation of PC.
  • In the low grade gliomas, phospholipase A(1) and lysophospholipase are upregulated and phospholipase D is downregulated, supporting the accumulation of GPC.
  • The present findings offer a promising procedure that will potentially help to accurately grade glioma tumors using (1)H HR-MAS, providing in addition the genetic background for the alterations of choline metabolism observed in high and low grade gliomas.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Biopsy. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Biopsy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19322812.001).
  • [ISSN] 1099-1492
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 60M22SGW66 / Glycerylphosphorylcholine; N91BDP6H0X / Choline
  •  go-up   go-down


86. Wong VC, Ma J, Hawkins CE: Telomerase inhibition induces acute ATM-dependent growth arrest in human astrocytomas. Cancer Lett; 2009 Feb 8;274(1):151-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase inhibition induces acute ATM-dependent growth arrest in human astrocytomas.
  • The purpose of the study was to examine the degree of hTERT, the catalytic subunit of telomerase, expression in paediatric high-grade astrocytoma and to explore the potential of telomerase inhibition as a therapy for these tumours. hTERT was expressed at high levels in 36 of 44 paediatric astrocytomas.
  • Telomerase inhibition induced acute DNA damage and ATM-pathway-dependent G2/M cell cycle arrest in astrocytomas in vitro, both occurring prior to telomere shortening itself.
  • Our data suggest that telomerase inhibition could be a useful adjuvant therapy for high-grade astrocytomas, potentially inducing tumour growth arrest following short-term treatment.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Cycle Proteins / metabolism. Cell Proliferation. DNA-Binding Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Telomerase / antagonists & inhibitors. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Cell Cycle / physiology. Child. DNA Damage. Flow Cytometry. Humans. Immunoenzyme Techniques. Telomere / physiology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945545.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


87. Makino K, Nakamura H, Yano S, Kuratsu J, Kumamoto Brain Tumor Group: Population-based epidemiological study of primary intracranial tumors in childhood. Childs Nerv Syst; 2010 Aug;26(8):1029-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common tumor was astrocytoma (35.7%) with an annual incidence rate of 13.2 per million, followed by germ cell tumor (14.3%, 5.0 per million), craniopharyngioma (10.5%, 3.8 per million), medulloblastoma (10.0%, 3.7 per million), and ependymoma (4.8%, 1.5 per million).
  • The distribution of the tumor type varied with the patient age and gender.
  • Although there were no germ cell tumors in 0- to 4-year-old boys, they were the second-most common tumor in 10- to 14-year-old boys.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1986;2(5):233-7 [3791280.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):1961-71 [16919764.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):198-203 [10207928.001]
  • [Cites] Pediatr Neurosurg. 2008;44(2):97-103 [18230922.001]
  • [Cites] Childs Nerv Syst. 1998 Jul;14(7):302-11 [9726580.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2064-80 [16919771.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):87-98 [19020806.001]
  • [Cites] Int J Epidemiol. 1994 Jun;23(3):458-64 [7960369.001]
  • [Cites] Childs Brain. 1977;3(2):69-78 [862464.001]
  • [Cites] Cancer. 1999 May 1;85(9):2077-90 [10223251.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):401-411 [19562257.001]
  • [Cites] Childs Nerv Syst. 2002 Feb;18(1-2):30-7 [11935241.001]
  • [Cites] Acta Paediatr. 2009 Oct;98(10):1620-7 [19594464.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:289-93 [16700303.001]
  • [Cites] Int J Clin Oncol. 2001 Aug;6(4):183-91 [11706556.001]
  • [Cites] Childs Nerv Syst. 1985;1(1):39-44 [3857124.001]
  • [Cites] Pediatr Neurosurg. 2005 Jul-Aug;41(4):173-7 [16088251.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jul;53(1):13-6 [19260104.001]
  • [Cites] Cancer. 1977 Dec;40(6):3123-32 [201364.001]
  • (PMID = 20349186.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Wang LW, Shiau CY, Chung WY, Wu HM, Guo WY, Liu KD, Ho DM, Wong TT, Pan DH: Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience. J Neurosurg; 2006 Dec;105 Suppl:127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience.
  • OBJECT: The authors report the long-term treatment results of Gamma Knife surgery (GKS) for patients with low-grade astrocytomas who underwent surgery at a single institution.
  • METHODS: A series of 21 patients (median age 20 years) with 25 intracranial low-grade astrocytomas (World Health Organization Grades I and II) were treated with GKS between 1993 and 2003.
  • Tumor volumes ranged from 0.2 to 13.3 ml (median 2.4 ml).
  • Complete tumor remission was seen in three patients.
  • Tumor progression was found in six patients of whom five received further salvage treatment.
  • All the tumor progression occurred within the GKS-treated volumes.
  • CONCLUSIONS: Gamma Knife surgery provides durable long-term local tumor control with acceptable toxicity for some patients with highly selected low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503345.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. De Falco G, Bellan C, D'Amuri A, Angeloni G, Leucci E, Giordano A, Leoncini L: Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors. Cancer Biol Ther; 2005 Mar;4(3):277-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cdk9 and Cyclin T1 expression levels were monitored during the differentiation program of neuroblastoma and astrocytoma cell lines.
  • Our results suggest that Cdk9/Cyclin T1 complex may be required for neuron differentiation induced by retinoic acid, because the expression level of the complex varies during differentiation, but no significant changes were observed in its expression in the astrocytoma cell line.
  • In addition, the expression of Cdk9 and Cyclin T1 was evaluated by immunohistochemistry in samples of neuroblastoma, PNET (Primary Neuroectodermal Tumor) and astrocytoma tumors of different grades, in order to assess whether there was a correlation between Cdk9 expression and tumor grading.
  • Our results show that in neuroblastoma and PNET tumor samples Cdk9 is more expressed the more differentiated the tumor is.
  • Conversely, no significant alteration of Cdk9 expression was observed in astrocytoma tumor samples of different grades, thus confirming the results obtained for the cell lines.
  • [MeSH-minor] Astrocytes / cytology. Astrocytes / drug effects. Astrocytes / pathology. Cell Differentiation. Cell Line, Tumor. Cyclin T. Cyclins / analysis. Cyclins / genetics. Cyclins / metabolism. Humans. Immunohistochemistry. RNA, Messenger / analysis. RNA, Messenger / metabolism. Tretinoin / pharmacology


90. Ranza E, Facoetti A, Morbini P, Benericetti E, Nano R: Exogenous platelet-derived growth factor (PDGF) induces human astrocytoma cell line proliferation. Anticancer Res; 2007 Jul-Aug;27(4B):2161-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exogenous platelet-derived growth factor (PDGF) induces human astrocytoma cell line proliferation.
  • In astrocytoma, PDGF ligand and receptor are often overexpressed and PDGFR activity deregulation has been linked to pathogenesis.
  • The issue of the functional capacity of PDGFR has only occasionally been addressed in glioma cells by measuring the proliferative response induced by exogenous PDGF.
  • In the present study, PDGFRalpha expression was evaluated in human grade 2 and 4 astrocytoma cell lines and tissue specimens by immunocytochemistry.
  • The receptor responsiveness to exogenous PDGF was determined in astrocytoma cells with an MTT assay.
  • It was found that astrocytoma cells express PDGFRalpha and respond to PDGF mitogenic action in a grade-dependent manner.
  • We can thus conclude that the proliferative response of human astrocytoma cells is related to their malignancy and receptor status before PDGF stimulation, suggesting a role for PDGFRalpha inhibitors as blockers of malignant cell proliferation.
  • [MeSH-major] Astrocytoma / pathology. Platelet-Derived Growth Factor / pharmacology
  • [MeSH-minor] Cell Growth Processes / drug effects. Cell Line, Tumor. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695499.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


91. Nagai S, Kurimoto M, Ishizawa S, Hayashi N, Hamada H, Kamiyama H, Endo S: A rare astrocytic tumor with rhabdoid features. Brain Tumor Pathol; 2009;26(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare astrocytic tumor with rhabdoid features.
  • We report an extremely rare tumor presenting with rhabdoid features in the left temporoparietal lobe near the trigone in an 18-year-old Japanese man.
  • This tumor mainly consisted of medium to large round cells that proliferated diffusely and incoherently with a scant extracellular matrix.
  • These tumor cells had an eccentric nucleus and an eosinophilic cytoplasm containing inclusion bodies and bundles of intermediate filaments.
  • This tumor had an area appearing to be diffuse astrocytoma peripherally and lacked a primitive neuroectodermal tumor component, a mesenchymal component, and epithelial differentiation.
  • INI expression, which is not observed in atypical teratoid/ rhabdoid tumor (AT/RT), was found in this tumor.
  • From these findings, we concluded that this tumor was not AT/RT but an astrocytic tumor with rhabdoid features.
  • We also concluded that the tumor cells exhibiting rhabdoid features had secondarily arisen from the peripheral area presenting an appearance of diffuse astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Rhabdoid Tumor / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408093.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. O'Shaughnessy J, Bussières A: Subtle clinical signs of a spinal cord ependymoma at the cervicothoracic level in an adult: a case report. J Can Chiropr Assoc; 2006 Dec;50(4):244-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtle clinical signs of a spinal cord ependymoma at the cervicothoracic level in an adult: a case report.
  • Due to the progressive nature of the neurological deficit, the patient was referred for a neurological consultation.
  • A magnetic resonance imaging (MRI) study was performed and revealed an expansive intramedullary lesion between C6 and T1 suggesting a differential diagnosis of spinal cord ependymoma or astrocytoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spinal Cord. 1999 Nov;37(11):753-9 [10578245.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] Neurosurgery. 1992 Feb;30(2):202-7 [1545888.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):523-32 [2319309.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):842-5 [2585075.001]
  • [Cites] Surg Neurol. 1988 Apr;29(4):271-81 [3353839.001]
  • [Cites] J Neurooncol. 1996 Aug;29(2):183-8 [8858524.001]
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Childs Nerv Syst. 1998 Aug;14(8):357-61 [9753400.001]
  • [Cites] Br J Neurosurg. 1997 Dec;11(6):542-53 [11013626.001]
  • [Cites] J Neurooncol. 2000 May;47(3):211-8 [11016737.001]
  • [Cites] Korean J Radiol. 2002 Oct-Dec;3(4):219-28 [12514338.001]
  • (PMID = 17549184.001).
  • [ISSN] 0008-3194
  • [Journal-full-title] The Journal of the Canadian Chiropractic Association
  • [ISO-abbreviation] J Can Chiropr Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1840009
  •  go-up   go-down


93. Pitchford CW, Schwartz HS, Atkinson JB, Cates JM: Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome. Am J Surg Pathol; 2006 Dec;30(12):1624-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome.
  • Neoplasms that commonly affect patients with neurofibromatosis type 2 (NF2) include schwannomas, meningiomas, astrocytomas, ependymomas, and neurofibromas.
  • This case represents the first report of a soft tissue perineurioma arising in the setting of NF2.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cytoplasm / ultrastructure. Diagnosis, Differential. Humans. Male. Neoplasms, Multiple Primary. Peripheral Nervous System Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122521.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


94. Stark AM, Modlich S, Claviez A, van Baalen A, Hugo HH, Mehdorn HM: Congenital diffuse anaplastic astrocytoma with ependymal and leptomeningeal spread: case report. J Neurooncol; 2007 Sep;84(3):325-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital diffuse anaplastic astrocytoma with ependymal and leptomeningeal spread: case report.
  • [MeSH-major] Astrocytoma / congenital. Astrocytoma / secondary. Brain Neoplasms / congenital. Brain Neoplasms / pathology. Ependymoma / secondary. Meningeal Neoplasms / secondary


95. Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF: Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol; 2010 May;119(5):641-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.
  • Pilocytic astrocytoma (PA) is the most common glioma in the pediatric population.
  • Parameters included quantification of characteristic morphologic variables as well as genes and molecular loci previously shown to be of relevance in high-grade gliomas, including 1p, 9p, 10q, 17p, 19q, and BRAF.
  • [MeSH-major] Astrocytoma / genetics. Brain / pathology. Brain Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics. Spinal Cord Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044755.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS37704
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


96. Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH: Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Rep Med; 2009;2009:757898
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common brain tumors, found in 15%-20% of NF1 patients, are hypothalamic-optic gliomas, followed by brainstem and cerebellar pilocytic astrocytomas.
  • NF1 patients are predisposed to a 5-fold increased incidence of high-grade astrocytomas, which are usually located in supratentorial regions of the brain.
  • We present an NF1 patient who developed a high-grade astrocytoma in the posterior fossa and discuss possible pathophysiological mechanisms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Med Genet. 1999 Dec;36(12):893-6 [10593996.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] J Biol Chem. 2005 Oct 14;280(41):34924-32 [16079146.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1699-702 [16033085.001]
  • [Cites] Pediatr Neurol. 2005 Apr;32(4):221-8 [15797177.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):71-4 [15655144.001]
  • [Cites] Neuroradiology. 1997 Sep;39(9):639-41 [9335062.001]
  • [Cites] Am J Hum Genet. 1993 Aug;53(2):305-13 [8328449.001]
  • [Cites] Glia. 1992;6(1):1-8 [1355074.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1225-9 [3080222.001]
  • [Cites] Ophthalmology. 1984 Aug;91(8):929-35 [6436764.001]
  • [Cites] J Neurosci Res. 2004 Mar 15;75(6):817-24 [14994342.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • [Cites] Neurochem Int. 2003 Dec;43(7):621-8 [12892649.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):759-61 [12221173.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Brain Res. 2000 Dec 29;887(2):250-8 [11134613.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):203-7 [11119704.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Pediatrics. 2000 Mar;105(3 Pt 1):608-14 [10699117.001]
  • [Cites] J Comp Neurol. 2005 Dec 19;493(3):370-80 [16261532.001]
  • (PMID = 20029672.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2796235
  •  go-up   go-down


97. Trinh VA, Patel SP, Hwu WJ: The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf; 2009 Jul;8(4):493-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the US and the EU, TMZ is licensed for the treatment of glioblastoma multiforme concurrently with radiation followed by a maintenance treatment, and for refractory anaplastic astrocytoma or glioblastoma multiforme.
  • CONCLUSION: For a cytotoxic cancer-treatment agent, TMZ has an acceptable safety profile.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19435405.001).
  • [ISSN] 1744-764X
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 43
  •  go-up   go-down


98. Koga N, Ishikawa H: [Clinical evaluation of primary position upbeat nystagmus]. Nippon Ganka Gakkai Zasshi; 2005 Apr;109(4):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were located in the median portion of the cerebellum and medulla oblongata except for one adult patient with astrocytoma.
  • [MeSH-minor] Adult. Aged. Astrocytoma / complications. Brain Neoplasms / complications. Cerebellum / pathology. Cerebrovascular Disorders / complications. Child. Child, Preschool. Female. Humans. Male. Medulla Oblongata / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859150.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology; 2009 Nov 24;73(21):1792-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
  • BACKGROUND: Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been implicated in tumorigenesis of gliomas.
  • Patients with high-grade astrocytomas with IDH1 or IDH2 mutations were reported to have a better survival, but it is unknown if this improved survival also holds for low-grade astrocytoma and whether these mutations predict outcome to specific treatment.
  • METHODS: We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy.
  • RESULTS: IDH1 mutations were present in 86% of the 49 progressive astrocytomas.
  • CONCLUSION: These results indicate that IDH1 mutations identify a subgroup of gliomas with an improved survival, but are unrelated to the temozolomide response.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma. Brain Neoplasms. Dacarbazine / analogs & derivatives. Isocitrate Dehydrogenase / genetics. Mutation / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933982.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


100. Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A: Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. Neurosci Lett; 2008 Jun 13;438(1):22-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated whether IFN-alpha/beta, IFN-gamma, or human immunodeficiency virus (HIV) induce neopterin production by human astroglioma cells.
  • In contrast, IFN-alpha/beta, but not IFN-gamma, reduced the uptake of three aromatic amino acids in U87MG and U138 astroglioma cells.
  • [MeSH-minor] AIDS Dementia Complex / immunology. AIDS Dementia Complex / metabolism. AIDS Dementia Complex / physiopathology. Brain / immunology. Brain / metabolism. Brain / virology. Cell Line, Tumor. Humans. Indoleamine-Pyrrole 2,3,-Dioxygenase / drug effects. Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism. Tryptophan / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457922.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amino Acids, Aromatic; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 0 / Interferon-alpha; 670-65-5 / Neopterin; 82115-62-6 / Interferon-gamma; 8DUH1N11BX / Tryptophan
  •  go-up   go-down






Advertisement